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1. INTRODUCTION 
Ribosome is a big nucleoprotein complex (molecular weight 2.5 MD), Es­
cherichia coli ribosome contains three different RNAs and 54 ribosomal pro­
teins. Its function is to synthesize proteins according to mRNA program. Dur­
ing this process ribosome interacts with many ligands. mRNA determines the 
sequence of the synthesized polypeptide. It interacts mainly with the small ribo­
somal subunit. tRNA brings activated amino acids to the ribosome. According 
to the classical model there are three tRNA binding sites in the ribosome: one 
for aminoacyl-tRNA (A site), one for peptidyl-tRNA (P site) and one for 
nonaminoacylated tRNA (E site) (Fig. 1). In all three sites tRNA has contact 
with rRNA (Noller, 1991) and ribosomal proteins (Wower et al., 1995). Two 
elongation factors interact with the ribosome: EF-Tu brings aminoacyl-tRNA to 
the ribosomal A site and EF-G catalyzes translocation of tRNAs from A site to 
P site and from P site to E site after peptide bond formation. Several regions of 
rRNA and ribosomal proteins are involved in the interactions with the elonga­
tion factors (Möller and Maassen, 1986; Noller, 1991). 
In addition to the well known interactions between ribosome and its ligands 
mentioned above, there is one more interaction that is often dismissed. It is the 
interaction between ribosome and nascent peptide. Formation of the peptide 
bond is catalyzed by the ribosomal peptidyl transferase center. Nascent peptide 
exits the ribosome through a tunnel (Yonath et al., 1987) or channel (Ryabova 
et al., 1988). Recently it has been discovered that there is bigger communica­
tion between the ribosome and the nascent peptide than thought before. It has 
been shown that protein folding can start already on the ribosome (Kolb et al., 
1994; Hardesty et al., 1995; Komar et al., 1997). And nascent peptide can 
regulate the work of the ribosome (Chapter 2.2.). 
Ribosomal ligands described above are all ubiquitous parts of the normal 
translational machinery. In addition to the usual ligands there are also ribo­
somal ligands of big practical importance that do not help to synthesize proteins 
but inhibit the process instead. These molecules are called antibiotics. One of 
the ribosome targeted antibiotics is erythromycin which is widely used in medi­
cal practice. Erythromycin binds to the nascent peptide binding site and blocks 
growth of the nascent peptide chain (Chapter 2.1.). Antibiotic resistance is a 
growing problem in the treatment of infections. And the same problem is pres­
ent with erythromycin — resistance has been described in many medical iso­
lates. In some cases the resistance mechanism is known but there are also cases 
where resistance mechanism is not clear. 
In the present work a new erythromycin resistance mechanism mediated by 
small ribosome-targeted peptides is described. First, relevant literature about 
erythromycin and ribosome-targeted peptides is reviewed. In the second part 
experimental results are discussed. 
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tRNA aminoacyl-tRNA 
EF-Tu EF-G nascent peptide 
Figure 1. The three site model for the elongation cycle. E site tRNA is released and 
[aminoacyl-tRNA: EFTu: GTP] complex binds to the A site (1). GTP is hydrolyzed and 
[EF-Tu: GDP] complex leaves the ribosome; aminoacyl-tRNA in the A site is ready to 
act as acceptor in the peptidyl transferase reaction (2). Peptidyl transferase reaction oc­
curs (3). EF-G catalyzes translocation of the peptidyl-tRNA from A site to P site and 
nonaminoacylated tRNA from P site to E site; during this process one GTP molecule is 
hydrolyzed (4). 
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2. REVIEW OF LITERATURE 
2.1. Erythromycin 
Macrolides are a group of commonly used antibiotics. They all contain a large 
lactone ring of 12-22 atoms which contains few or no double bonds and no ni­
trogen atoms; in addition they have one or more sugars attached to the lactone 
ring (Pestka, 1977). Erythromycin is the most widely used macrolide with 
14 atom lactone ring and two attached sugars (Fig. 2). Erythromycin inhibits 
protein synthesis in procaryotes but not in eukaryotic cytoplasm or mitochon­
dria (Pestka, 1977). 
Figure 2. Chemical structure of erythromycin (Pestka, 1977). 
The single binding site of erythromycin is located on the large ribosomal 
subunit in the vicinity of the peptidyl transferase center (Vazquez, 1979). 
23S RNA has direct role in erythromycin binding because: (i) postranscrip-
tional methylation of rRNA can confer resistance, (ii) mutations in rRNA can 
confer resistance, and (iii) erythromycin protects nucleotides in the 23S RNA 
from chemical modification. 
o 
"Q 
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The drug binds to vacant ribosomes or large ribosomal subunits and inhibits 
protein synthesis (Vazquez, 1979). Erythromycin causes the breakdown of 
polysomes and ribosomes enter a cycle of repetitive abortive initiations (Tai et 
al1974). Andersson and Kurland (1987) studied the effect of erythromycin on 
ß-galactosidase synthesis in vivo and concluded that an initial stage of transla­
tion is susceptible to erythromycin while the elongating ribosome is insensitive 
to the drug action. In the model peptidyltransferase reaction erythromycin does 
not inhibit formation of the first peptide bond. However it inhibits peptidyl­
transferase when the donor substrate has peptide chain from two to five amino 
acids in length (Mao and Robishaw, 1972). Erythromycin does not inhibit 
translation when the nascent peptide chain is longer than 5 amino acids (Vester 
and Garrett, 1987). Peptidyl-tRNAs are released from the ribosome in response 
to erythromycin treatment, suggesting that erythromycin and peptidyl-tRNA 
have overlapping binding sites (Otaka and Kaji, 1975; Menninger and Otto, 
1982). 
From these observations it has been suggested that erythromycin inhibits 
nascent peptide growth only in a narrow window of the peptide length of 2 to 
5 amino acids: during the synthesis of the first peptide bond the nascent chain 
does not reach the erythromycin binding site and after the nascent chain is 
longer than 5 amino acids the binding site is covered and erythromycin cannot 
bind (Vester and Garrett, 1987; Weisblum, 1995b). 
It has been reported recently that erythromycin inhibits also assembly of the 
50S subunit (Chittum and Champney, 1995). For inhibition of cell growth the 
effects of the drug on nascent peptide growth and 50S subunit assembly seem 
to contribute equally (Ghampney and Burdine, 1996). The mechanism how 
erythromycin inhibits 50S subunit assembly is currently not known. 
The known mechanisms of erythromycin resistance include active efflux of 
the drug from the cell, modification of erythromycin and modification of ribo­
somal RNA (methylation or mutation of 23S rRNA bases) and ribosomal pro­
tein mutations. Active efflux mediated by a membrane transporter is a common 
cause for high level resistance (Weisblum, 1995a). Structural modification of 
erythromycin includes phosphorylation (Ohara et al., 1989), glycosylation 
(Jenkins and Cundliffe, 1991), and lactone ring cleavage by erythromycin es­
terase (Ounissi and Courvalin, 1985; Arthur et al., 1987). 
Methylation of the 23S RNA resulting in erythromycin resistance occurs at 
nucleotide A2058 and was originally observed in clinical isolates of Staphylo­
coccus aureus (Lai and Weisblum, 1971; Lai et al., 1973; Skinner et al., 1983). 
The gene responsible for methylation was designated as ermA. Later additional 
erm genes from other organisms have been found. The Erm family comprises a 
group of homologous methylases that use S-adenosylmethionine (SAM) as the 
methyl donor to modify a single adenine residue in the 23S rRNA to form ei­
ther N6-mono- or dimethyladenine (Weisblum, 1995a). There appear to be at 
least two functionally different classes of Erm methylases. The first class in-
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eludes those that only monomethylate adenine, e.g., Lrm from Streptomyces 
lividans (Jenkins and Cundliffe, 1991), Clr from Streptomyces caelestis 
(Calcutt and Cundliffe, 1990), and TlrD from Streptomyces fradiae (Zalacain 
and Cundliffe, 1991). The second class includes enzymes that predominantly 
dimethylate adenine, e.g. ErmC from'S. aureus (Denoya and Dubnau, 1989), 
ErmE from Saccharopolyspora erythrea (Calcutt and Cundliffe, 1990) and 
TlrA from S. fradiae (Zalacain and Cundliffe, 1989). 
Mutations at three nucleotides in the 23S RNA are known to cause erythro­
mycin resistance. All the three positions are located close to each other in the 
secondary structure model (Fig. 3) (Brimacombe et al., 1990). Mutations 
C2611U (Vannuffel et al., 1992; Harris et al., 1989) and C2611G (Harris et al., 
1989) affect 5' half of helix 73, mutations G2057A (Ettayebi et al., 1985), 
A2058G (Vester and Garrett, 1987) and A2058U (Sigmund et al., 1988) affect 
3' half of the same helix. Location of erythromycin binding site at the base of 
helix 73 is also confirmed by footprinting studies (Moazed and Noller, 1987). 
The drug protects bases A2058 and A2059 from dimethylsulfate modification; 
in addition, erythromycin also strongly protects G2505 (Fig. 3). Erythromycin 
resistance mutations are also described in domain II of 23S RNA (Douthwaite 
et al., 1985, 1989). Their mechanism of action will be discussed in chapter 3.4. 
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Figure 3. Secondary structure model of the central part of 23S rRNA domain V. Nu­
cleotides protected from chemical attack by erythromycin are circled; mutations leading 
to erythromycin resistance are indicated by arrows. 
Though rRNA is important for erythromycin binding, ribosomal proteins also 
contribute to the formation of erythromycin binding site. Mutations in ribo-
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somal proteins L4 and L22 are known to cause erythromycin resistance in labo­
ratory isolates (Wittmann et al., 1973; Pardo and Rosset, 1977; Arevalo et al., 
1988). Erythromycin can be chemically crosslinked to L22 (Arevalo et al., 
1988). L4 and L22 are associated with domain I of the 23S RNA (Liiv et al., 
1996). These data are not easily compatible with the known erythromycin 
binding site in domain V. At least L4 can influence erythromycin binding indi­
rectly, through RNA conformation/50S subunit assembly, similarly to the 
streptomycin resistance conferred by mutations in S12 (Noller et al., 1990). 
Erythromycin resistance mutations in ribosomal proteins have never been ob­
served in clinical isolates, probably because of their temperature-sensitive phe-
notype and severe defects in ribosome assembly (Pardo et al, 1979). Ribo­
somal protein L15 has been shown to bind erythromycin in solution (Teraoka 
and Nierhaus, 1978), but the binding affinity is three orders of magnitude lower 
than the binding between ribosomes and erythromycin (affinity constant 
10"8 M) (Pestka et al., 1976). 
2.2. Peptides and ribosomes 
(Reference I) 
It is frequently assumed that the ribosome is indifferent to the sequence of the 
newly synthesized polypeptides. This concept, which stems from the fact that 
various cellular proteins are efficiently assembled by the ribosome, is however, 
oversimplified and there are a number of examples when amino acid sequence 
of the nascent peptide affects ribosome functions (Lovett and Rogers, 1996). 
Translational attenuation is used in bacteria to regulate expression of chlo-
ramphenicol-resistance (cat and cmlA) and erythromycin-resistance (erm) genes 
in response to low concentrations of the corresponding drugs (Lovett, 1990; 
Weisblum, 1995b). The ribosome binding sites of these antibiotic resistance 
genes are sequestered in the RNA secondary structure; ribosome stalling at a 
specific codon of a short ORF preceding the resistance cistron changes the sec­
ondary structure of mRNA and permits translation of the downstream main 
ORF. Such stalling occurs at codon 6 of the cat leader ORF and at codon 9 of 
the leader ORFs of cmlA and erm genes. Curiously, ribosome stalling depends 
on the amino acid sequence of the translated short peptide; missense mutations 
in the leader ORF changing the nature of the encoded amino acids reduced effi­
ciency of induction of the main cistron translation (Mayford and Weisblum, 
1989, 1990; Gu et al., 1994a). In the stalled ribosome, the nascent peptide is 
present in the form of peptidyl-tRNA and, thus, is positioned close to the pepti­
dyl transferase center. Synthetic peptides corresponding to the first 5 codons of 
cat or first 8 codons of cmlA leader ORFs were able to inhibit in vitro peptidyl 
transferase reaction (Gu et al., 1993, 1994b). Therefore, Lovett and co-workers 
have suggested that the nascent peptide causes site-specific pausing of transla­
tion by inhibiting activity of the peptidyl transferase (Gu et al., 1993); it has 
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been proposed further that the pausing ribosome is converted into the stalled 
state by the inducer, chloramphenicol. However, since little similarity can be 
found between cat, cmlA, and erm leader peptides, it remains unclear what 
properties of the peptide are important for its regulatory effect. Similar to the 
cases of translational attenuation, sequence of the peptide translated from the 
leader ORF has been shown to be important for transcriptional attenuation of 
the E. coli tryptophanase operon (Gish and Yanofsky, 1995). 
Regulation of translation, mediated by ribosome stalling on short upstream 
open reading frames (uORFs), was described also for several eukaryotic genes 
(Geballe and Morris, 1994). In some of these cases stalling depends on the se­
quence of the translated peptide rather than on the sequence of mRNA. For ex­
ample, expression of the glutaminase subunit of carbamoyl-phosphate synthase 
A (CPA1) in yeast is controlled posttranscriptionally by the concentration of 
arginine (Messenguy et al., 1983). The arginine-dependent repression of CPA1 
translation requires the presence of a 25 codon uORF in the 250 nucleotide 
long leader region of the CPA1 mRNA (Werner et al., 1987). It seems plausible 
that the nascent uORF-encoded peptide remains associated with the translating 
ribosome, causing it to stall and preventing it from proceeding to the initiation 
codon of the CPA1 ORF. Interestingly, fusion of the first 23 codons of the 
uORF in frame with an ORF of a reporter protein made expression of this pro­
tein repressible by arginine, indicating that precise termination of CPA1 uORF 
translation is not required for the regulatory function of the encoded peptide 
(Delbecq et al., 1994). Functional analogue of CPA1 in Neurospora crassa, 
arg-2, is regulated in a similar way to CPA1. 
There are also several other examples were translation of the uORF is in­
hibiting translation of the main ORF. For mammalian S-adenosyl methionine 
decarboxylase (Hill and Morris, 1993), ß2 adrenergic receptor (Parola and Ko-
bilka, 1994), Lc transcriptional activator of maize (Damiani and Wessler, 1993) 
and cytomegalovirus glycoprotein gene gp48 (Degnin et al., 1993) it has been 
shown that the peptide coded by the uORF is important for inhibition of trans­
lation. In these cases it has been shown that proper placing of the termination 
codon is important; when the uORF is fused to a longer ORF then the inhibitory 
effect is no longer present. For gp48 it has been shown that ribosome stalls at 
the stop codon of the uORF and therefore creates a block for scanning ribo­
somes (Cao and Geballe, 1996a). It seems that the nascent peptide inhibits ter­
mination because the peptide stays in the ribosome in the form of peptidyl-
tRNA (Cao and Geballe 1996b). 
An exciting example of the influence of nascent peptide on ribosome func­
tion has been described by Weiss et al. (1990). Bacteriophage T4 gene 
60 mRNA contains an internal 50 nucleotide long untranslated coding cap, 
separating the first 46 codons of the gene from the last 114 codons. This cap is 
not excised from the RNA as an intron but rather is bypassed by elongating ri­
bosomes. Nascent peptide amino acids 17 to 32 are implicated in activating 
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such ribosome hopping, though the exact requirements for peptide sequence 
remains obscure. However, in another described example of translational by­
pass, the nascent peptide sequence is apparently not important (Benhar and 
Engelberg-Kulka, 1993). 
In all the cases described above the regulatory (in most cases inhibitory) 
properties of the nascent peptide are probably caused from specific interaction 
of the peptide with the ribosome. What is known about interaction of different 
peptides with the ribosome? First, in the classic "fragment reaction" experi­
ments, the efficiency of peptidyl transfer correlates with the chemical structure 
of the donor amino acid residue, which structurally and functionally corre­
sponds to the C-terminal amino acid of the nascent peptide (Krayevsky and 
Kukhanova, 1979). Second, the termination of translation may be influenced by 
the protein's last two amino acids. Lysine is found more frequently at the 
C-termini of proteins in which ORF is terminated at UAA, while a similar po­
sition is occupied more often by phenylalanine, or serine in case of the UGA 
stop codon (Arkov et al., 1993). Issakson and co-workers demonstrated that the 
frequency of read-through of UGA and UAG termination codons depends on 
the penultimate amino acid. (Mottagui-Tabar et al., 1994). Termination is in­
hibited by several (or most?) regulatory peptides. In the case of the cat leader 
peptide it has been shown that synthetic peptide inhibits in vitro termination 
reaction (Moffat et al., 1994). For gp48, the fact that ribosome stops on termi­
nation codon in complex with peptidyl-tRNA indicates that uORF coded pep­
tide inhibits termination (Cao and Geballe, 1996b). 
In many (and maybe all) of the cases discussed above, newly synthesized 
peptide may exert its effect on translation while still located in the ribosome. 
However, interaction of the nascent peptides with external factors "outside" of 
the ribosome is also known to play a role in regulation of translation. The best 
characterized case is a transient arrest of translation during synthesis of se­
creted proteins when the signal recognition particle binds to the signal sequence 
of a secreted protein emerging from the ribosome and halts translation until the 
complex binds to a docking protein in the membrane (Walter and Johnson, 
1994). Another example of cotranslational interaction of the nascent peptide 
with external factors outside of the ribosome comes from the studies of regula­
tion of ß-tubulin synthesis. Increased concentration of free ß-tubulin subunits in 
the cell triggers the degradation of ß-tubulin mRNA in polysomes (Cleveland, 
1989). The four N-terminal amino acids of ß-tubulin nascent peptide are essen­
tial for such autoregulation (Yen et al., 1988; Bachurski et al., 1994). When 
this segment of the nascent peptide is blocked by antibodies, the tubulin-
dependent autoregulation is prevented, suggesting that binding of additional 
factors (possibly, free ß-tubulin subunits) to the nascent peptide N-terminus is 
necessary for mRNA degradation (Theodorakis and Cleveland, 1992). 
For all of the examples described above it is common that the peptides can 
act only in eis, on the same ribosome where they have been synthesized. It is 
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likely that many of these peptides affect the ribosome while they are still bound 
in the nascent peptide channel. This is evident for the nascent regulatory pep­
tides of the bacterial antibiotic resistance operons. Translation of these peptides 
is not yet complete when they cause ribosome pausing; therefore, the peptide 
must still be in the form of peptidyl-tRNA. 
The sequences of the regulatory peptides discussed above are very different 
from each other, making it impossible to find structurally similar groups 
(Fig. 4). Moreover, there is no case where the sequence requirements are sys­
tematically studied. 
We have described a new example of nascent peptide regulation of transla­
tion and also characterized the peptide sequence requirements. 
ermC M G I F S I F V I S T V H Y O P N K K  
cat-86 M V K T D K I S S  
cmlA M  S T S K N A D  K  
AdoMetDC M A G  P I S  
gp48 MOPLVLSAKKLSSLLTCK Y I P P  
CPA1 M F S L S N S Q  Y T C Q D Y I S D H I W K T S S H  
B2 adrenergic receptor MKLPGVRPRPAAP R  R  R  C  T  R  
gene 60 MKFVKIDSSSVDMKK Y K L O N N V R R S I K S S S M  N Y A N V A I M T D A D H D G  
E-peptide in the 23S RNA M R M L T 
E-peptide from peptide library MSLKV 
Figure 4. Examples of short peptides involved in m-regulation of translation. Sequences 
correspond to the peptides involved in regulation of translation of cistrons coding for 
bacterial chloramphenicol (cat and cmlA) and erythromycin (ermC) resistance proteins, 
mammalian S-adenosyl methionine decarboxylase (AdoMetDC), glutaminase subunit of 
yeast carbamoyl phosphate synthase A (CPA1), cytomegalovirus glycoprotein gene 
(gp48), and murine ß2 adrenergic receptor. Also shown are 46 N-terminal amino acids of 
bacteriophage T4 gene 60 protein, E-peptide encoded in the Escherichia coli 23S RNA 
and E-peptide from random peptide library giving highest erythromycin resistance. 
Amino acids in which substitution affects functions of corresponding peptides are un­
derlined. 
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3. RESULTS AND DISCUSSION 
Ribosome is a big nucleoprotein complex and therefore very hard to study. 
Finding of functional subribosomal complexes is essential for understanding 
the ribosome at molecular level. In the current work a small functional part of 
ribosomal RNA was isolated and characterized. 
3.1, Experimental approach: libraries 
Libraries of biological macromolecules have been efficiently used to solve 
many biological problems. Genomic and cDNA libraries are routinely used for 
gene cloning and sequencing. Moreover, libraries can be used for functional 
mapping of a single gene. Using this strategy, random pieces of the gene are 
generated and expressed in vivo. If some pieces of the gene are coding for 
functional domains of the protein or RNA then they should interfere with the 
normal function of the gene. This approach has been used to search for regions 
in the genome of phage % responsible for resistance to hyperinfection 
(Holzmayer et al., 1992), to find genes responsible for anticancer drug resis­
tance in mammalian cells (Gudkov et al., 1994), for functional mapping of the 
gene for oncoprotein p53 (Ossovskaya et al., 1996) and to find new tumor sup­
pressor genes (Garkavtsev et al, 1996). 
We used a similar approach to study ribosomal RNA. Escherichia coli 
rRNA Operon was cut randomly into small fragments with DNasel (Fig. 5). The 
size of the fragments was from 100 to 1000 basepairs, coding potentially for 
RNA fragments ranging in size from small hairpins to secondary structure do­
mains. DNA fragments were cloned into two RNA expression vectors. In 
pPOTl, transcription starts from tac promoter and terminates on trp terminator. 
In pMAG transcription starts from rRNA promoter PI and terminates on rRNA 
terminators T1 and T2. Both plasmids have lac operator after the promoter that 
makes RNA expression inducible with IPTG. lac operator and the terminators 
code for RNA hairpins. RNA hairpins have been shown in many systems to 
stabilize RNA in the cell (McLaren et al,, 1991; Emory et al., 1992). The ex­
pression levels of RNA fragments from library plasmids were estimated on 
Northern blots using reporter constructs. It was found that both vectors express 
RNA in the cell at levels one or two orders of magnitude smaller than the 
amount of ribosomal RNA. The copy number of the vectors is around 60 com­
pared to the 7 ribosomal RNA Operons in the chromosome and the promoters 
should be as strong as chromosomal rRNA promoters. Therefore the small 
amount of the transcript is probably caused by instability of the small RNA 
fragments in the cell. For our studies it was desirable to have rRNA fragments 
in the cell at the level comparable to the amount of ribosomal RNA. To in­
crease the RNA level we tried to use T7 promoter directed expression system. 
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Unfortunately, there are two drawbacks of the T7 system. First, 23S RNA tran­
scribed by T7 polymerase has been shown to form inactive 50S subunits; the 
reason for the inactivity of the T7 transcript is not known (Lewicki et al., 
1993). Second, transcription with T7 polymerase significantly changes cell 
physiology which makes many in vivo screening schemes impossible or very 
difficult. Therefore we decided to continue our work using rRNA fragment li­
brary in expression vector pPOTl which expresses 1.5-2 times more RNA in 
the cell than the vector pMAG. 
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Figure 5. Construction of the random rRNA fragment library. 
3.2. E-peptide 
(Reference II) 
The first selection scheme used to look for functional rRNA fragments was se­
lection for rRNA fragments that render cells resistant to ribosome targeted an­
tibiotics. When cells carrying library plasmids were plated on plates containing 
erythromycin and JPTG several colonies appeared. Erythromycin resistance 
was shown to be dependent on the presence of rDNA-containing plasmids 
rather than chromosomal mutations, since Eryr phenotype of the selected clones 
cotransferred with the plasmids. Furthermore, transcription of a plasmid-borne 
rDNA segment was essential for erythromycin resistance, because transformed 
cells exhibited Eryr phenotype only in the presence of IPTG, an inducer of the 
tac promoter. The rRNA fragments produced in these clones were designated 
E-RNA for erythromycin resistance RNA. All the analyzed rDNA inserts from 
>20 different Eryr clones overlapped in the region corresponding to positions 
1233-1348 of the 23S RNA (Fig. 6). In all the clones, the inserts were present 
in the direct orientation so that their transcription should result in production of 
sense 23S rRNA fragments. The smallest of the E-RNAs in the selected Eryr 
clones corresponded to a 116 nucleotide long segment of the 23S rRNA; subse­
quent deletion analysis showed that expression of an rRNA fragment only 
34 nucleotides long (E-RNA34), corresponding to the 23S rRNA sequence 
between positions 1235 and 1268, could render cells resistant to erythromycin 
(Fig. 7). 
Figure 6. Positions of the eRNA (bold line) and erythromycin footprints (dots) in the 
secondary structure model of the 23S rRNA. 
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Figure 7. The nucleotide sequence and secondary structure of the E. coli wild-type 23S 
rRNA segment encoding the pentapeptide mini-gene. The minimal rRNA fragment ca­
pable of conferring erythromycin resistance (E-RNA34) is shown in boldface. Shine-
Dalgarno region of the pentapeptide gene is boxed, and the sequence of the encoded 
peptide is indicated. 
To get insights into the mechanism of E-RNA action, mutations were intro­
duced randomly into the E-RNA. Distribution of mutations that abolished 
E-RNA activity revealed two critical regions: GUG at positions 1248-1250 and 
UAA at positions 1263-1265. Remarkably, these two segments correspond to 
initiator and terminator codons of a pentapeptide ORF present in E-RNA. 
Moreover, a canonical Shine-Dalgarno sequence, GGAGGU (positions 1235-
1240), which is essential for initiation of translation in prokaryotes (Shine and 
Dalgarno, 1974), is present seven nucleotides upstream from the initiator 
codon, at the 5'-end of E-RNA, and is important for its function, because its 
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deletion renders E-RNA inactive. These results raised the possibility that ex­
pression of a 23S rRNA-encoded pentapeptide Met-Arg-Met-Leu-Thr 
(E-peptide) may be required for the observed erythromycin resistance. 
To verify that the putative ribosome binding site of the E-peptide mini-gene 
could direct initiation of translation, the first 16 nucleotides of E-RNA34, com­
prising the putative Shine-Dalgarno sequence and the initiator GUG codon, 
were fused to the second codon of the chloramphenicol acetyltransferase re­
porter gene. Cells, transformed with the resulting chimeric construct, became 
resistant to chloramphenicol and significant chloramphenicol acetyltransferase 
activity was detected in the cell extracts. This result confirmed that the putative 
ribosome binding site of the pentapeptide mini-gene present in the E.coli 23S 
RNA can be efficiently used for initiation of translation. 
To directly test whether translation of the E-peptide mini-gene was required 
for erythromycin resistance, we investigated whether function of an E-RNA 
with a nonsense mutation in the peptide ORF can be restored in the presence of 
a suppressor tRNA. We used E-RNA34 mutant, in which E-RNA function was 
abolished by a nonsense mutation in the second codon of the mini-gene, which 
converted the arginine codon CGA into the opal stop codon UGA. As a nega­
tive control, we used another inactive E-RNA mutant with a mutation in the 
initiator codon. A gene of the opal suppressor tRNA^8 (McClain et al., 1990), 
expressed from its own promoter, was introduced into the same plasmid, and 
phenotypes of the transformed cells were assessed by plating on antibiotic-
containing agar plates. Presence of the suppressor tRNAArg restored ability of 
the UGA mutant, but not the CUG mutant, to confer resistance to erythromycin, 
thus proving that synthesis of the rRNA-encoded E-peptide was necessary for 
drug resistance. 
Effects of the E-peptide and E-RNA on translation apparatus were studied in 
the cell-free translation system. The synthetic E-peptides, MRMLT and 
N-formyl-MRMLT, did not influence erythromycin sensitivity of in vitro pro­
tein synthesis up to 1 mM of the peptide concentration. Yet, when E-RNA was 
added to the cell-free system, instead of the E-peptide, a reproducible protec­
tion against erythromycin was observed. Without the E-RNA, translation of the 
phage MS2 RNA was reduced 3-fold in the presence of 0.4-0.8 jLtg of erythro­
mycin per ml. If, however, ribosomes were allowed to translate E-RNA before 
addition of the phage RNA, then residual protein synthesis in the presence of 
erythromycin was 2-fold higher. Because E-RNA reduces the effects of eryth­
romycin not only in vivo but also in vitro, the translation apparatus appears to 
be a likely target of action of the rRNA-encoded peptide. These data also sug­
gest that the peptide can act only on the same ribosome where it was synthe­
sized (eis-mode of action). This can explain the inactivity of the synthetic pep­
tide. 
The E-peptide is reminiscent of the cat, cmlA, and erm leader peptides 
(Chapter 2.2.) in its size and czs-mode of action. Therefore, it is likely that all 
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of these peptides may interact with the same site in the vicinity of the peptidyl 
transferase center, probably overlapping with the erythromycin binding site. 
3.3. Libraries again 
(Reference IV) 
To elucidate sequence requirements for the E-peptide we decided to create a 
big collection of active peptides. To achieve this, we used random mini-gene 
libraries. The libraries, where each bacterial cell expresses a specific mini-gene 
coding for an oligopeptide, were subjected to phenotypic selection based on 
IPTG-inducible erythromycin resistance. Two libraries were used: one of them 
has 5 (4 of them randomized) and the other 21 (20 of them randomized) codons 
in the ORF. Comparing sequences of peptides encoded in the mini-genes in 
erythromycin resistant cells isolated from 21-codon and 5-codon random li­
braries allowed us to draw first conclusions about the sequence and size re­
quirements for the peptide activity. Screening of the 21-codon library revealed 
the preferred size of erythromycin resistance peptides. There are 3 termination 
codons in the genetic code. Accordingly, the probability that out of 20 random 
codons none will be a terminator codon is (61/64)20 = 0.38, and thus, about 2/3 
of the clones in the 21-codon library are expected to have in-frame stop codons. 
Therefore, this library provides a very good tool for investigating the size re­
quirement for functional peptides. As expected, a broad distribution of sizes of 
the encoded peptides were found in unselected, randomly picked clones. In 
contrast, the majority of peptides expressed in Ery1 clones fell within an amaz­
ingly narrow size range; 11 out of 12 peptides were four, five or six amino ac­
ids long. Of course, there is a possibility that a more extensive screening could 
reveal some functional peptides larger than hexapeptides; nevertheless, this ex­
periment showed a clear tendency of erythromycin resistance peptides to be 
four to six amino acids long. In agreement with this conclusion, the originally 
described rRNA-encoded E-peptide was five amino acids long. 
Previously it had been demonstrated that any mutation eliminating the stop 
codon of the rRNA-encoded E-peptide abolished erythromycin resistance. This 
showed that a mere presence of the E-peptide sequence at the N-terminus of a 
longer polypeptide could not render ribosomes resistant to erythromycin. The 
results of screening a 21-codon library not only confirmed this conclusion, but 
also indicated that proximity of the "active" sequence to the peptide C-terminus 
was also not sufficient for erythromycin resistance (otherwise we could isolate 
clones coding for long peptides where critical sequence would be located close 
to the C-terminus). Thus, we can conclude an erythromycin resistance peptide 
cannot be part of a longer protein and the size of the peptide is essential for its 
activity. The strict size requirement for peptide activity may mean that the pep­
tide binding site is not very big and cannot accommodate a longer polypeptide. 
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If analysis of clones isolated from the 21-codon library revealed peptide size 
preference, then screening the 5-codon library provided clues to the sequence 
features that are important for E-peptide activity. Comparison of sequences of 
52 pentapeptides found in Eryr clones showed a strong tendency for having Leu 
or lie in the third position and a hydrophobic amino acid in the C-terminal po­
sition. Not only did these sequence signatures appear in the majority of isolated 
E-peptides, but there was also a definite correlation of peptide activity with the 
presence of Leu or lie in the third position and a hydrophobic amino acid at the 
C-terminus. 
Interestingly, if E-peptides act in the immediate vicinity of peptidyl trans­
ferase center so that the C-terminal peptide residue is positioned in the P-site, 
then the third residue from the C-terminus would be located very close to the 
erythromycin binding site since the drug starts to inhibit protein synthesis at a 
step when the third amino acid is added to the growing nascent peptide (Mao 
and Robishaw, 1972). Also noteworthy is the fact that 5 out of 12 peptides ex­
pressed in Eryr clones isolated from the 21-codon library have either Leu or lie 
in position -3 relative to the C-terminus. The bulky hydrophobic side-chain of 
leucine or isoleucine may interfere with interaction of erythromycin with its 
binding site in the vicinity of the peptidyl transferase center. 
Expression of E-peptide rendered cells resistant to other macrolide antibiot­
ics, oleandomycin, which similar to erythromycin, has a 14-atom lactone ring 
and to spiramycin, a macrolide with a 16-atom ring. At the same time, 
E-peptide did not affect cell sensitivity to structurally different chlorampheni­
col and clindamycin. All tested drugs compete with erythromycin for binding to 
the ribosome (Chang et al., 1969), however, the binding sites of chlorampheni­
col and clindamycin do not precisely coincide with the binding site of macrol-
ides as demonstrated by RNA footprinting and the difference in the mode of 
action of these drugs (Moazed and Noller, 1987; Vazquez, 1979). Thus, the site 
of E-peptide action probably overlaps specifically with binding site of macrol-
ides, but not with that of other antibiotics interacting with the ribosome in the 
vicinity of the peptidyl transferase center. 
A model of how E-peptide may interact with the ribosome and cause eryth­
romycin resistance is shown in Fig. 8. The binding site of E-peptide is located 
most probably in the large ribosomal subunit, in or immediately near the nas­
cent peptide channel, and overlaps with the erythromycin binding site (which is 
shown in gray in Fig. 8). The peptide has to be placed in this site co-
translationally from the peptidyl transferase side which would explain a 
ds-mode of E-peptide action. Three positions in E-peptide appear to be impor­
tant for peptide activity. Besides Leu or lie in the third position and a hydro­
phobic residue (more frequently Val) at the C-terminus, the N-terminal formyl-
methionine may be also essential. 
Though importance of fMet is difficult to assess since by default it is present 
in all library-coded E-peptides, the fact that E-peptide cannot be part of a longer 
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protein indicates that the position or formylation of the N-terminal methionine 
is critical for peptide activity. Amino acids located in the critical positions of 
the peptide may form specific contacts with the ribosome (shown by thin lines 
in the figure). One or several E-peptide amino acids may overlap with the 
erythromycin binding site thus conferring resistance to the drug. Lack of resis­
tance to peptidyl transferase inhibitors chloramphenicol and clindamycin sug­
gests that E-peptide does not overlap with the binding site of these drugs on the 
ribosome. The simplest explanation of how E-peptide can protect the ribosome 
from antibiotic action is that the E-peptide remains associated with the ribo­
some after completion of its translation and prevents binding of the drug to the 
ribosome. The presence of E-peptide on the vacant ribosome should make it 
immune to erythromycin. When translation of a new protein is initiated, the 
nascent peptide may possibly go "around" the bound E-peptide, or alterna­
tively, displace it. 
30S SUBUNIT 
peptidyl 
transferase 
center 50S SUBUNIT 
Ery 
Figure 8. A model of E-peptide action. Erythromycin binding site (Ery) is shown gray 
and binding sites of chloramphenicol (Cam) and clindamycin (Cid) are shown as open 
triangles. The third position of the peptide commonly represented by Leu (as shown in 
the figure) or lie is assumed to overlap with the erythromycin binding site. The con­
served peptide positions, N-terminal formyl methionine, the third Leu (or lie) and 
C-terminal hydrophobic amino acid (commonly represented by Val, as shown in the 
figure) may form specific contacts with rRNA or ribosomal proteins. 
Our random peptide library approach has a number of advantages compared to 
the other combinatorial methods exploiting libraries of synthetic peptides 
(Houghten, 1993) or phage display libraries (Scott and Smith, 1990). Firstly, it 
is much easier to synthesize a random DNA sequence of the peptide gene than a 
random amino acid sequence of the peptide itself, leading to better representa­
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tion of a random peptide sequence space in a mini-gene library compared to 
synthetic peptide libraries. Secondly, phenotypic selection permits not only 
screening of hundreds of thousands of peptide sequences in a single experi­
ment, but also to amplify the "signal" (the selected sequence) by allowing cells 
that passed the selection to form colonies; signal amplification is usually im­
possible with the use of synthetic peptide libraries. Thirdly, in contrast to phage 
display libraries where a random amino acid sequence is expressed as a seg­
ment of a large protein, the mini-gene library peptides are expressed in their 
free form which can be critical for assessing functionality of the random se­
quence. For example, inasmuch as E-peptides cannot act as a part of a longer 
protein, isolation of E-peptides from a phage display library would be impossi­
ble. In our experiments, we used random mini-gene libraries for isolation of a 
particular class of functional peptides. Similar approach can be used for isola­
tion of other functional peptides which may serve as enzyme co-factors, in­
hibitors, etc. 
3.4. Translation of ribosomal RNA 
(Reference III) 
Originally, ribosomal RNA was perceived as a messenger RNA that encodes 
proteins (Crick, 1958). This view later underwent a transition: for a time, rRNA 
was considered to be a scaffold for the ribosomal proteins; nowadays, rRNA is 
more commonly viewed as a functional, maybe even catalytic, constituent of 
the ribosome (Noller et al., 1990). Still, the idea that the most abundant RNA 
may also carry protein-coding information was not abandoned completely. At­
tempts to find protein genes in the rRNA have been undertaken; a few rela­
tively long suspicious open reading frames have been identified (Brosius et al., 
1978; Peng et al., 1992) and that translation of one of such ORFs is possible 
has been demonstrated (Berg et al., 1987). Nevertheless, the translation prod­
ucts of these ORFs were never detected and functions of the putative proteins 
were never recognized. 
Finding of the E-peptide raises the question about translation of ribosomal 
RNA again. In our experiments, E-peptide was translated from a rRNA frag­
ment expressed from a strong plasmid promoter. It is unclear yet whether 
E-peptide is expressed naturally. In the intact ribosome, the peptide mini-gene 
apparently remains cryptic because its ribosome-binding site is sequestered in 
the rRNA secondary structure. As is evident, the E-peptide expression can be 
activated by a specific RNA fragmentation. Cutting of the rRNA in the apex 
stem-loop of the helix at positions 1198-1247 of the 23S rRNA (Fig. 7), which 
may happen, for example, under conditions of physiological stress, can gener­
ate translatable rRNA fragments leading to production of the E-peptide. Spe­
cific fragmentation of ribosomal RNA has been shown to occur in apoptotic 
mammalian cells (Houge et al., 1995). 
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Mutations are yet another way to activate expression of the rRNA-encoded 
E-peptide. A spontaneous deletion of 12 nucleotides (positions 1219-1230) 
from the 23S rRNA gene has been described as causing resistance to erythro­
mycin (Douthwaite et al., 1985, 1989). The effect of this deletion in domain II 
was difficult to reconcile with the known location of the erythromycin-binding 
site in domain V of the 23 S rRNA. Our results offer a new explanation for the 
erythromycin resistance caused by deletions in domain II. The 12-nucleotide 
deletion destabilized the hairpin at positions 1198-1247, thus making the ribo-
some-binding site of the E-peptide mini-gene more accessible and activating 
E-peptide expression. Analysis of effects of other deletions and nucleotide sub­
stitutions in the hairpin at positions 1198-1247 on erythromycin resistance 
strongly supports our explanation. 
3.5. Concluding remarks 
We have found that a small fragment of 23S RNA can be translated to a func­
tional pentapeptide. This ORF is present in large subunit rRNA of most eubac-
teria and many eukaryotes. The fact that E-peptide ORF is not universally con­
served can explained in two ways: first, the E-peptide can be a regulatory mole­
cule used for fine turning of translation, it is not absolutely essential and is lost 
in many organisms; second, the presence of the E-peptide ORF in the rRNA can 
be a coincidence. If the presence of the E-peptide ORF has some function, then, 
obviously, erythromycin resistance is not its primary function. What can be its 
function remains unclear. Unclear is also in what physiological conditions 
could E-peptide be expressed. 
From the other hand, we have described a new mechanism of antibiotic re­
sistance which can account for Eryr phenotypes of some clinical bacterial iso­
lates. Mutations not only in rRNA but also in mRNA can create short ORFs 
which can code for functional peptides. E-peptide is also a new addition to the 
growing number of eis-acting regulatory peptides. 
The amount of E-RNA accumulated in Eryr clones was relatively low, about 
1 mol % of the amount of 5S RNA, and was not enough to directly affect a sig­
nificant portion of the ribosome population or to sequester a substantial amount 
of intracellular erythromycin. Translation of E-RNA resolves this contradiction, 
because multiple E-peptide molecules can be translated from one molecule of 
E-RNA. The low amount of expressed RNA is hindering the use of our rRNA 
fragment libraries. Therefore it is surprising that Prescott's group, using similar 
approach found a fragment of 16S RNA which gives resistance to the 30S 
subunit targeted antibiotic spectinomycin (Howard et al., 1995). The fragment 
corresponds to the known binding site of spectinomycin to the 16S RNA and 
therefore it was proposed that the RNA fragment works by sequestering the 
drug. Unfortunately, the amount of the spectinomycin resistance RNA in the 
cell was not estimated and the resistance mechanism has not been published. 
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The peptide library can be used to find other functionally active peptides. 
Indeed, using negative selection with cycloserine we found several peptide 
mini-genes with cytostatic activity. According to the puls-labelling experi­
ments, at least some of the cytostatic peptides are inhibiting protein synthesis. 
Studying of such inhibitory peptides may yield further insight in interactions 
between the ribosomes and nascent peptides. 
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4. CONCLUSIONS 
1. A new mechanism of antibiotic resistance, mediated by interaction of small 
peptides with the ribosome has been described. 
2. Possibility of translation of a small open reading in the 23S RNA was dis­
covered. 
3. The mechanism of erythromycin resistance caused by mutations in domain 
II of 23S rRNA was explained; it is mediated by activation of translation of 
the functional peptide encoded in 23S rRNA. 
4. A method to study functions of small peptides in the cell and find new 
pharmaceuticals based on in vivo expression of the random peptide libraries 
has been developed. 
5. Sequence requirements for the erythromycin resistance peptides were char­
acterized and the mechanism of interaction of short peptides with the ribo­
some has been proposed. 
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RIBOSOOMID, PEPTIIDID JA ANTIBIOOTIKUMI 
RESISTENTSUS 
Kokkuvõte 
Ribosoomid seonduvad translatsioonitsükli vältel hulga molekulidega: tRNAde 
ja translatsioonifaktoritega. Peale selle seonduvad ribosoomid mitme anti-
biootikumiga. Ühelgi juhul ei ole teada täpset ribosoomi piirkonda, mis seon­
dumise eest vastutab. 
Käesoleva töö eesmärk oligi funktsionaalsete subribosomaalsete komplek­
side isoleerimine. Eeldati, et ekspresseerides rakus funktsionaalseid ribosoomi-
RNA (rRNA) fragmente, võiksid need mõjutada translatsiooniprotsessi. Val­
mistati juhuslike rRNA-fragmentide ekspressiooni kogu ja selekteeriti erütro-
mütsiiniresistentseid kloone. Selgus, et erütromütsiiniresistentsust põhjustab 
23S RNA teise domeeni fragmentide ekspressioon rakus. 
Deletsioonanalüüs võimaldas isoleerida minimaalse funktsionaalse frag­
mendi. See on 34 nukleotiidi pikk, vastates 23S RNA positsioonidele 1235 kuni 
1268. Mutatsioonanalüüs näitas, et erütromütsiiniresistentsuseks võib olla olu­
line selles fragmendis asuv avatud lugemisraam, mille ees on translatsiooni 
initsiatsiooniks vajalik Shine'i-Daigarno järjestus. Kui fragmendi 5'osa, kuni 
lugemisraami teise koodonini, klooniti kloramfenikool-atsetüülitransferaasi 
geeni translatsiooni initsiatsiooni ala asemele, siis täheldati kloramfenikool-
atsetüülitransferaasi sünteesi. Seega võimaldab 23S RNA fragmendi initsiaa-
torkoodon ja sellele eelnev ala translatsiooni initsiatsiooni. Seega võis oletada, 
et erütromütsiiniresistentsuse põhjustab sünteesitav pentapeptiid MRMLT. 
Selle hüpoteesi kontrollimiseks kasutasime mutanti, mille teine koodon oli 
muteeritud arginiini kodeerivast CGA-koodonist UGA-terminaatorkoodoniks. 
Selline mutant põhjustas erütromütsiiniresistentsust ainult supressor-tRNA 
juuresolekul, mis kodeerib UGA-koodonit arginiiniga. Sellest võib järeldada, et 
erütromütsiiniresistentsuseks on tõepoolest vajalik pentapeptiidi translatsioon. 
In vitro translatsiooni süsteemis keemiliselt sünteesitud pentapeptiidi lisamine 
resistentsust ei põhjustanud. Seevastu tekkis resistentsus, kui ribosoomidele 
lisati rRNA fragment ja lasti transleerida peptiid. Sellest võib oletada, et peptiid 
mõjub in eis: ainult sellele ribosoomile, kus ta sünteesid. 
Selgitamaks, millised peptiidi omadused on vajalikud erütromütsiiniresis­
tentsuse põhjustamiseks, konstrueeriti kaks raamatukogu. Esimene ekspres-
seerib rakus RNAsid, milles on olemas translatsiooni initsiatsiooniks vajalikud 
järjestused ja initsiaatorkoodonile järgneb 20 juhuslikku koodonit. Kuna 3 koo-
donit 64st on terminaatorkoodonid, siis on 2/3-1 avatud lugemisraamidest 
sisemine terminaatorkoodon. Sellisest raamatukogust erütromütsiiniresistent-
seid kloone selekteerides selgus, et peptiid peab olema 3 kuni 6 aminohapet 
pikk. Et esimesest raamatukogust selekteeritud kloonide hulk oli väike, konst-
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rueeriti peptiidi järjestusele esitatavate nõuete selgitamiseks ka teine raamatu­
kogu. See on analoogne esimesega, välja arvatud see, et initsiaatorkoodonile 
järgneb ainult neli juhuslikku koodonit. Sellest raamatukogust selekteeritud 
järjestuste analüüsimisel selgus, et enamus peptiide sisaldab leutsiini või iso-
leutsiini jääki kolmandas positsioonis ja hüdrofoobset aminohapet C-termi-
nuses. 
Erütromütsiin inhibeerib translatsiooni, blokeerides kasvava polüpeptiidi 
liikumist. Erütromütsiin ei ihhibeeri esimese peptiidsideme sünteesi ega polü-
soome, kus kasvav peptiid on pikem kui viis aminohapet. Seega võib oletada, et 
erütromütsiini seondumispiirkond kattub selle alaga, kuhu seonduvad ka kas­
vava peptiidi C-terminusest kolmas, neljas ja viies aminohape. Esimese peptiid­
sideme sünteesi ajal ei ole kasvav peptiid veel erütromütsiini seondumiskohani 
jõudnud ja seega inhibeerimist ei toimu. Kui peptiid on üle viie aminohappe 
pikk, siis katab ta erütromütsiini seondumiskoha ja järelikult ei saa erütromüt­
siin enam seonduda. Seega võib oletada, et resistentsust põhjustavad peptiidid 
jäävad ribosoomile pidama ega lase erütromütsiinil seonduda. Järgmine süntee-
sitav valk kas lükkab peptiidi välja või saab temast kuidagi ümbert mööda. 
Eelnevalt oli teada, et erütromütsiiniresistentsust põhjustavad mutatsioonid 
23S RNA viiendas domeenis, seal paikneb ka nukleotiid A2058, mille 
metüülimine põhjustab resistentsust. Peale selle kaitseb erütromütsiin kemi­
kaalide eest kolme viienda domeeni nukleotiidi (A2058, A2059 ja G2505). 
Seega tundub igati loogiline, et erütromütsiini seondumispiirkond asub viiendas 
domäänis. Mõni aasta tagasi aga isoleeriti deletsioonid teises domeenis, mis 
põhjustavad samuti erütromütsiiniresistentsust. Nende funktsioneerimis-
mehhanism sai selgeks siis, kui analüüsiti teise domeeni mutantide mõju pen­
tapeptiidi sünteesile. Erütromütsiiniresistentsust määrava peptiidi lugemisraami 
ees olev Shine'i-Dalgarno järjestus on tugevas sekundaarstruktuuris ja seega on 
metsikut tüüpi 23S RNA translatsioon võimatu. 23S RNA fragmentatsioon või 
mutatsioonid, mis nõrgendavad sekundaarstruktuuri, võimaldavad aga peptiidi 
translatsiooni ja põhjustavad seega erütromütsiiniresistentsust. 
Jääb ebaselgeks, kas 23S RNAd transleeritakse kunagi ka looduslikes 
tingimustes või oli leitud peptiid lihtsalt juhus. Sellele vaatamata on käesolevas 
töös kirjeldatud uudset antibiootikumiresistentsuse mehhanismi ning juhitud 
tähelepanu võimalusele, et ribosoomi tööd võib reguleerida kasvav peptiid. 
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Comparison of functional peptide 
encoded in the Escherichia coli 23S 
rRNA with other peptides involved in 
eis-regulation of translation 
Tanel Tenson and Alexander Mankin 
Abstract: A new approach for studying functional rRNA fragments has been developed based on using a 
plasmid library expressing random fragments of rRNA, A 34 nucleotide long fragment of Escherichia coli 
23S rRNA has been identified that renders cells resistant to erythromycin, when expressed in vivo. The rRNA 
fragment contains a five codon long open reading frame, initiating at GUG and terminating at UAA, with a 
Shine-Dalgamo sequence located at an appropriate distance from the initiator codon. Translation of this 
mini-gene is required for the observed erythromycin resistance. Experiments with in vitro translated, or 
synthetic, peptide indicate the ribosome as a likely target for the action of the identified rRNA-encoded peptide, 
which apparently remains associated with the ribosome after completion of its translation. The known 
properties of the rRNA-encoded peptide are compared with information about other functionally active short 
peptides that can be involved in regulation of translation. 
Key words: ribosome, rRNA, peptide, translation, erythromycin. 
R&um£ : Les fragments fonctionnels de I'ARNr ont ete etudies par une nouvelle approche qui utilise une 
banque de Plasmides exprimant des fragments aleatoires d'ARNr. Nous avons identify un fragment de 34 
nucleotides de I'ARNr 23S de Escherichia coli qui, lorsqu'exprime in vivo, rend les bacteries resistantes ä 
I'erythromycine. Le fragment d'ARNr contient un cadre de lecture constitue de cinq codons, debutant ä GUG et 
se terminant ä UAA, et une sequence Shine-Dalgamo localisee a une distance adequate du codon d'initiation. 
La traduction de ce minigene est requise pour que la resistance ä I'erythromycine soit acquise. Des experiences 
effectuees avec un peptide traduit in vitro ou synthetique indiquent que le ribosome est probablement le site 
d'action du peptide cod£ par I'ARNr, celui-ci demeurant apparemment associe au ribosome ä la fin de la 
traduction. Les proprietes du peptide code par I'ARNr sont comparees ä Celles d'autres petits peptides actifs qui 
interviendraient dans la regulation de la traduction. 
Mots cles : ribosome, ARNr, peptide, traduction, erythromycins. 
[Traduit par la redaction] 
Introduction 
Originally, ribosomal RNA was perceived as a messenger 
RNA that encodes proteins (Crick 1958). This view later 
underwent a transition: for a time, rRNA was considered to be 
a scaffold of the ribosome; nowadays, rRNA is more com­
monly viewed as a functional, maybe even catalytic, constitu­
ent of the ribosome (Noller et al. 1990). Still, the fascinating 
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open reading frames in eukaryotic mRNAs; SRP, signal 
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idea that the most abundant cellular RNA may also carry pro-
tein-coding information was not abandoned completely. 
Attempts to find protein genes in the rRNA have been repeat­
edly undertaken; a few relatively long, suspicious open read­
ing frames have been identified (Brosius et al. 1978; Peng et 
al. 1992) and the possibility of translation of one of such ORFs 
has even been demonstrated (Berg et al. 1987). Nevertheless, 
the translation products of these ORFs were never detected 
and functions of the putative proteins were never recognized. 
Until now, however, the possibility that some smaller open 
reading frames in rRNA may have functional significance has 
been essentially ignored. Such short ORFs (4-8 codons), some 
equipped with reasonable translation initiation signals, are 
present in almost any long rRNA. It is known that translation 
of short ORFs plays an important role in several regulatory 
mechanisms in the cell, the best example of which is attenua­
tion of transcription and translation (Landick and Yanofsky 
1987; Lovett 1990). Biological activity of short peptides has 
been well documented (Alberts et al. 1994), and some antibi-
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Fig. 1. Construction of random rRNA fragment library. The library was constructed in a specially 
designed pPOT plasmid vector that contains IFTG-inducible Ptac promoter (with lacO operator), 
attached via Nhel linker to trpl terminator; laclq gene ensures efficient repression of the Ptac 
promoter under noninduced conditions. For the library construction, E. coli rrnB operon rDNA was 
partially hydrolyzed with DNase I; resulting fragments were ligated with Spe\ linkers and 
introduced into the Nhel site of the pPOT vector. Plasmid library was transformed into E, coli JM 
109 cells and screened for the presence of clones expressing functional rRNA fragments. The bottom 
part of the figure represents the generalized structure of the rRNA transcripts expressed from the 
library plasmids. Terminal hairpins correspond to the quasi palindromic sequences of the lac 
operator and trp terminator and may increase stability of the transcript in the cell. 
Ptac lacO trpT 
pPOTl 
library of random 
rDNA fragments 
rRNA fragment 
L/WWWl 
otics of peptide nature are capable of specific interaction with 
the ribosome (Vazquez 1979). Therefore, it would not be 
senseless to suggest that one or several short ORFs, or encoded 
peptides, present in rRNA may be functionally meaningful. 
Unfortunately, it was not clear how to approach the possible 
function of the encoded peptides. 
The primary goal of our studies was not the isolation of pro­
tein-coding regions of rRNA. We developed a novel approach 
that, in our belief, should allow us to isolate various functional 
segments of rRNA. The idea behind the method is very simple; 
random fragments of rRNA are expressed in the cell and 
clones expressing functionally active fragments are selected. 
Here we use a rather broad operational definition of the word 
"functional" as we apply this term to any fragment of rRNA 
that, when expressed in vivo, can modulate ribosome func­
tions in any possible way. Thus, rRNA fragments sequestering 
one or several ribosomal proteins or translation factors, frag­
ments interfering with inter-domain or subunit interactions, 
fragments capable of binding antibiotics, fragments competing 
with the ribosome for binding to tRNA or mRNA, fragments 
assisting or interfering with ribosome assembly, etc., all will 
considered functional. What we had not considered possible 
was that some rRNA fragments may be functional because 
they can direct the synthesis of the proteins encoded therein. 
Nevertheless, when in the course of these experiments we 
identified several fragments of the 23S rRNA that were able to 
confer erythromycin resistance, it turned out that a short open 
reading frame present in these fragments (and thus in the 23S 
rRNA) must be expressed to make cells resistant to the drug. 
The accumulated data indicate that the ribosome is a likely tar­
get for the action of the identified rRNA-encoded peptide, 
which apparently remains associated with the ribosome after 
completion of its translation. 
In this paper, we compare data obtained in our laboratory 
on the structural and functional features of the rRNA-encoded 
peptide with information about other functionally active pep­
tides that can affect translation in eis. 
Effect of the rRNA-encoded peptide on ribosome function 
To understand the functions of individual segments of rRNA, 
a plasmid library expressing random rRNA fragments was 
prepared (Fig. 1). Random rDNA fragments ranging in size 
from —40 to 500 bp were generated from the rrnB operon of 
E. coli and inserted into the newly constructed plasmid vector 
pPOT where they were transcribed from the IPTG-inducible 
tac promoter. (The details of the library construction will be 
published elsewhere.) Such a library can be screened in vivo 
by a variety of functional tests. In our experiments leading to 
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the finding of the rRNA-encoded peptide, the library was 
screened for rRNA fragments that rendered cells resistant to 
ribosome-targeted antibiotics. One of the antibiotics used for 
screening was erythromycin, which is known to interact with 
the large ribosomal subunit. Although the exact mechanism of 
erythromycin action remains largely speculative, results 
obtained in different laboratories suggest that it may inhibit 
protein synthesis by sterically hindering growth of the nascent 
peptide chain (Vester and Garrett 1987). 
Screening the rRNA fragment library for erythromycin-
resistant clones resulted in the selection of a number of clones 
that, in the presence of IPTG, were able to grow at erythromy­
cin concentration of 150-200 |xg/mL (the growth of the cells 
transformed with the empty vector was efficiently inhibited at 
a concentration of 50 p.g/mL erythromycin). The rDNA inserts 
in all selected Eryr clones were derived from the 23S rRNA 
gene and encompassed the region from position 1200 to 1300 
at the junction of domains II and III of the 23S rRNA (Fig. 2). 
Subsequent deletion analysis showed that expressions of 
rRNA fragments as short as 34 nucleotides long (positions 
1235-1268) could render cells resistant to erythromycin. This 
rRNA fragment was named eRNA34 (for effector RNA). Fur­
ther deletion of 4 nucleotides from the 5' end or 7 nucleotides 
from the 3' end of eRNA34 rendered it inactive. Mutation 
analysis revealed three regions of eRNA34 that were critical 
for its activity: GGAGG sequence at the beginning of the 
eRNA34, GUG sequence 8 nucleotides downstream, and 
UAA sequence 12 nucleotides further downstream (Fig. 2C). 
The relative distribution and the sequences of these elements 
led to the striking possibility that translation of the short open 
reading frame present in the eRNA34 may be required for its 
activity in conferring erythromycin resistance. This ORF is 
equipped with a Shine-Dalgamo sequence GGAGG; it starts 
at GUG and terminates at the UAA codon and codes for a pen-
tapeptide, Met-Arg-Met-Leu-Thr, which was named e-pep-
tide, for the effector peptide. Fusion of the first 16 nucleotides 
of eRNA34, from the Shine-Dalgamo region to the first codon 
of the e-peptide ORF, with the second codon of the chloram­
phenicol acetyl transferase gene resulted in efficient expres­
sion of the reporter gene, indicating that the ribosome binding 
site of eRNA34 can indeed be used for initiation of translation. 
The hypothesis that translation of the e-peptide was neces­
sary for the observed erythromycin resistance was directly 
tested using an eRNA34 mutant with a point mutation at the 
second codon, which converted it into the stop codon UGA. 
The mutant eRNA34 was inactive and cells expressing it 
remained sensitive to erythromycin. However, introduction 
into the cell for a UGA suppressor tRNAAr8 gene concomi­
tantly with the mutant eRNA34 restored eRNA34 activity and 
made cells erythromycin resistant. Thus, it is evident that the 
mechanism of eRNA34 action is mediated by synthesis in the 
cell of the rRNA-encoded pentapeptide. 
Among the different possible targets of e-peptide action, the 
ribosome appears to be the most probable one. This conclusion 
comes from in vitro studies of eRNA34 and e-peptide action. 
The phage MS2 RNA-directed cell-free translation system is 
sensitive to erythromycin. However, preincubation of the cell-
free translation reaction mixture with in vitro transcribed 
eRNA34, resulting in the e-peptide synthesis, reduced the inhib­
itory action of erythromycin by 15-25%. Interestingly, in vitro 
translated peptide remained bound to the ribosome and did not 
dissociate even during sucrose gradient centrifugation. When 
synthetic e-peptide was added to the cell-free translation system 
instead of eRNA, no clear effect on erythromycin sensitivity 
was observed. Taken together, these data can be interpreted in 
favor of the eis mode of e-peptide action, where the nascent e-
peptide translated from the rRNA fragment remains associated 
with the ribosome (maybe in the form of peptidyl-tRNA) and 
renders it resistant to erythromycin. 
An important question is the actual function of e-peptide in 
the cell, if any. Indeed, the cell could hardly foresee that its 
survival would be challenged by exposure to erythromycin. 
Hence, what is observed as erythromycin resistance is proba­
bly nothing but a side effect of a yet obscure activity of the e-
peptide related to protein biosynthesis. Interestingly, synthetic 
e-peptide present at 1-2 mM concentration can efficiently 
inhibit translation in the cell-free system by interfering with 
the peptidyl transferase reaction. 
There are several cases described in the literature where 
ribosome appears to interact in a specific manner with newly 
translated polypeptide and this interaction has functional con­
sequences for ribosome activity. Many properties of the e-
peptide (its small size, possible eis mode of action, effect on 
translation) are similar to those of nascent peptides involved in 
translation regulation. Therefore, comparing e-peptide with 
regulatory cis-acting peptides may provide leads to under­
standing its function and mode of interaction with the ribo­
some. The next section briefly summarizes experimental facts 
where involvement of ci's-acting newly synthesized polypep­
tides is proven or suspected. Discussion of some of these 
effects can be also found in recent reviews by Lovett (1994) 
and Geballe and Morris (1994). 
Effect of newly synthesized peptides on translation 
Nascent peptide-dependent stalling of the ribosome in 
bacterial antibiotic resistance genes 
Translational attenuation is used in bacteria to regulate ex­
pression of chloramphenicol-resistance (cat and cm/A) and 
erythromycin-resistance (erm) genes in response to low con­
centrations of the corresponding drugs. The ribosome binding 
sites of these antibiotic resistance genes are sequestered in the 
RNA secondary structure; ribosome stalling at a specific 
codon of a short open reading frame preceding the resistance 
cistron changes the secondary structure of mRNA and permits 
translation of the downstream main ORF (Lovett 1990). Such 
stalling occurs at codon 6 of the cat leader ORF and at codon 9 
of the leader ORFs of cmlA and erm genes (Fig. 3A). Curi­
ously, ribosome stalling depends on the amino acid sequence 
of the translated short peptide; missence mutations in the 
leader ORF changing the nature of the encoded amino acids 
reduced efficiency of induction of the main cistron translation 
(Mayford and Weisblum 1989, 1990; Gu et al. 1994a). In the 
stalled ribosome, the nascent peptide is present in the form of 
peptidyl-tRNA and, thus, is positioned close to the peptidyl 
transferase center. Synthetic peptides corresponding to the 
first 5 codons of cat or first 8 codons of cmlA leader ORFs 
were able to inhibit in vitro peptidyl transferase reaction (Gu 
et al. 1993, 19946). Therefore, Lovett and co-workers have 
suggested that the nascent peptide causes site-specific pausing 
of translation by inhibiting activity of the peptidyl transferase 
(Gu et al. 1993); it has been proposed further that the pausing 
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Fig. 2. Location in rrnB operon and structure of the rRNA fragments expressed in erythromycin-resistant library clones. (A) Relative 
location on the rrnB physical map of the inserts from several individual erythromycin-resistant library clones; the scale shows 23S rRNA 
numeration. (B) Position of the eRNA34 (bold line) in the secondary structure model of the 23S rRNA. (C) Structure of the eRNA34. 
Terminal hairpins corresponding to the lac operator and trp terminator are shown schematically. Shine-Dalgamo sequence, initiator GUG 
codon, and terminator UAA codons are underlined; amino acid sequence of the encoded pentapeptide is shown below and position numbers 
corresponding to the terminal nucleotides of the eRNA34 in the E. coli 23S rRNA are indicated. 
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ribosome is converted into the stalled state by the inducer, 
chloramphenicol. However, since little similarity can be found 
between cat, cm/A, and erm leader peptides, it remains unclear 
what properties of the peptide are important for its regulatory 
effect. 
Effect of eukaryotic upstream open reading frames on 
translation 
Protein synthesis in eukaryotes is usually initiated at the first 
AUG codon, present in the appropriate context, that is encoun­
tered by an initiation complex scanning in the 3' direction 
starting from the 5' end of mRNA (Kozak 1989). However, in 
about 10% genes, short upstream open reading frames 
(uORFs) are present in the 5' leader region of the transcript 
(Geballe and Morris 1994). Translation of such uORFs may 
influence expressions of the main cistron. There are several 
examples when not only the mere presence of an uORF but 
also the sequence of the encoded peptide is critical for regula­
tion of translation of the main ORF. 
Expression of the glutaminase subunit of carbamoyl-phos-
phate synthase A (CPAI) in yeast is controlled posttranscrip-
tionally by the concentration of arginine (Messenguy et ai. 
1983). The arginine-dependent repression of CPA 1 translation 
requires the presence of a 25 condon uORF in the 250 nucle­
otide long 5' leader region of the CPAI mRNA (Wemer et al. 
1987). Nonsence mutations in the 12th or 20th codons of the 
uORF, as well as missence mutations in codons 11 and 13, 
eliminate arginine-dependent regulation of CPAI translation 
and have a cis-dominant effect (Fig. 3A); silent mutations that 
preserved amino acid sequence of the uORF-encoded peptide 
have little influence on CPAI expression (Werner et al. 1987; 
Delbecq et al. 1994). It seems plausible that the nascent uORF-
encoded peptide remains associated with the translating ribo­
some, causing it to stall and preventing it from proceeding to 
the initiation codon of the CPAI ORF. Interestingly, fusion of 
the first 23 codons of the uORF in frame with an ORF of a 
reporter protein made expression of this protein repressible by 
arginine (Delbecq et al. 1994), indicating that precise termina­
tion of CPAI uORF translation is not required for the regula­
tory function of the encoded peptide. 
In the previous examples, the role of small cofactors (anti­
biotics or arginine) for the nascent peptide-mediated transla­
tional control seems to be important. However, this does not 
appear to be a universal rule and involvement of small cofac­
tors has not been demonstrated in a number of the following 
cases. Efficiency of expression of mammalian 5-adenosyl 
methionine decarboxylase (AdoMetDC) correlates with the 
density of ribosomes on AdoMetDC mRNA (Hill and Morris 
1992; Ruan et al. 1994). In T cells, ribosome occupation of 
AdoMetDC mRNA is inhibited to the extent where 
AdoMetDC mRNA is present primarily in monosomes. Such 
inhibition depends on the presence of a 6 codon long uORF in 
the mRNA leader region (Hill and Morris 1992). The sequence 
of the encoded hexapeptide is critical for the regulation of the 
ribosome loading, since missense mutations (but not wobble 
mutations) in the three carboxyl terminal codons of the uORF 
relieve translational repression (Hill and Morris 1993). It is not 
clear whether translation of the uORF causes ribosome stall­
ing, though it seems to be a likely hypothesis, especially taking 
into account that uORF produces its inhibitory effect in eis 
(Hill and Morris 1993). 
The expression of cytomegalovrius glycoprotein gene gp48 
is also modulated at the translational level (Schleiss et al. 
1991; Cao and Geballe 1994). Of the three uORFs present in 
the 5' leader region of the gp48 transcript, only the second 
uORF has an inhibitory effect on the translation of the gp48 
cistron (Schleiss et al. 1991). Analysis of missense and wob­
ble mutations within this 22-codon uORF showed that the 
sequence of the encoded peptide, not the presence of the ORF 
per se, was critical for inhibiting downstream translation 
(Degnin et al. 1993) (Fig. 3A). As in the previous cases, the eis 
dominant character of the uORF mutations has been demon­
strated (Degnin et al. 1993). 
A similar effect is caused by an upstream ORF present in 
the 5' leader region of ß2 adrenergic receptor mRNA (Parola 
and Kobilka 1994). The presence of this 19 codon long uORF 
is the cause of 50% repression of translation of the main cis­
tron. The location of the uORF, its size, and, to some extent, 
the sequence of the encoded arginine-rich peptide is conserved 
among mammals (Fig. 3A). The synthetic uORF-encoded 
peptide is active in vitro, where it can repress cell-free transla­
tion of several mRNAs. At least three of the arginines present 
in the C-terminal portion of the peptide sequence are essential 
for its activity. Replacement of these arginines by alanines 
alleviates the peptide inhibitory effect in vitro, and mutations 
of corresponding arginine codons in uORF increases expres­
sion of ß2 adrenergic receptor in vivo. Since it has been shown 
that arginine-rich peptides can bind to RNA in vitro (Calnan et 
al. 1991) and inasmuch as the mutations in the ß2 adrenergic 
receptor uORF had a dominant eis effect, it has been proposed 
that the newly synthesized 19 amino acid long arginine rich 
peptide binds to the same mRNA molecule from which it has 
been translated and prevents its translation (scanning) by fol­
lowing ribosomes (Parola and Kobilka 1994). An alternative 
possibility is that the nascent peptide remains associated with 
the translating ribosome, causing its stalling or preventing 
reinitiation at the AUG codon of the ß2 adrenergic receptor 
ORF. Interestingly, one other arginine-rich synthetic peptide 
(but not several other tested peptides) inhibited in vitro trans­
lation in a manner similar to the uORF-encoded peptide. 
Why E. coli ribosomes dislike chicken histone H5 
The importance of arginines for nascent peptide-mediated 
inhibition of translation emerges also in another case. The 
chicken histone H5 is efficiently translated in a rabbit reticu­
locyte system. However, it cannot be overexpressed in E. coli 
because of accumulation of unfinished nascent peptide inter­
mediates (Gerchman et al. 1994). This results from ribosome 
stalling in the mRNA region coding for the highly positively 
charged lysine and arginine-rich C-terminal tail of the protein. 
Attachment of the same Lys-Arg-rich gene segment to a 
reporter protein inhibited its translation as well. Interestingly, 
there were no problems in overexpressing histone HI, which 
also had highly positively charged C-terminal tail. The main 
apparent difference in structure of the C-terminal portions of 
H1 and H5 genes is that basic residues in the H1 tail are mostly 
lysines with many fewer arginines. Notably, not only a high 
concentration of arginine residues but also a high proline con­
tent is characteristic of both the H5 histone C-terminal tail and 
the putative inhibitory peptide encoded in the uORF of ß2 
adrenergic receptor mRNA (Gerchman et al. 1994; Parola and 
Kobilka 1994). Thus, it is possible that arginines and prolines 
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Fig. 3. Examples of short peptides involved in c/i-regulation of translation. (A) Sequences correspond to the peptides 
involved in regulation of translation of cistrons coding for bacterial chloramphenicol (cat and cm/A) and erythromycin (erm) 
resistance proteins, mammalian 5-adenosyl methionine decarboxylase (AdoMetDC), glutaminase subunit of yeast carbamoyl 
phosphate synthase A (CPAI), cytomegalovirus glycoprotein gene (gp48), and ß2 adrenergic receptor of different mammals. 
Also shown are 46 N-terminal amino acids of bacteriophage gene 60 protein. Amino acids in which substitution affects 
functions of corresponding peptides are underlined. (B) Amino acid sequences of pentapeptides in which expression in E. 
coli cells confers erythromycin resistance. The left column represents the sequence of the 23S rRNA-encoded e-peptide and 
some of its mutants generated by introducing limited number of mutations into the eRNA34; the right column shows 
sequences of the active pentapeptides selected from the library where the pentapeptide open reading frame in the eRNA34 
was completely randomized. 
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are important for translation inhibition by corresponding pep­
tides. 
Interestingly, arginine-proline-rich short peptide ORFs are 
found in leader regions of early genes of several papovaviruses 
(Khalili et al. 1987). The presence of these uORFs reduces 
translation of the main cistrons. Though direct involvement of 
the papovavirus early leader peptides in translation regulation 
has not been demonstrated directly, resemblance between 
these peptides and the Arg-Pro-rich peptides discussed above 
is highly suggestive of their functional similarity as well. 
Ribosome hopping depends on amino acid sequence of the 
nascent peptide 
An exciting example of the influence of nascent peptide on 
ribosome function has been described by Weiss et al. (1990). 
Bacteriophage T4 gene 60 mRNA contains an internal 50 
nucleotide long untranslated coding gap, separating the first 46 
codons of the gene from the last 114 codons. This gap is not 
excised from the RNA as an intron but rather it is bypassed by 
elongating ribosomes (Huang et al. 1988). Nascent peptide 
amino acids 17 to 32 are implicated in activating such ribosome 
hopping, though the exact requirements for peptide sequence 
remains obscure. The nascent peptide activates ribosome 
bypass only in eis, which is not surprising since the ribosome 
reaches the "take-off' site (codon 46) when the functionally 
active peptide segment, corresponding to amino acids 17-32, is 
still within the ribosome. It has been suggested that, analogous 
to the peptide antibiotic edein, the nascent peptide may desta­
bilize P-site tRNA binding and thus trigger the bypass (Weiss 
et al. 1990). However, in another described example of trans­
lational bypass, the nascent peptide sequence is apparently not 
important (Benhar and Engelberg-Kulka 1993). 
Peptidyl transfer and translation termination sensitivity to 
amino acid context 
Reactions catalyzed at the peptidyl transferase center of the 
ribosome are influenced by the nature of the nascent peptide 
C-terminal amino acids. In the classic "fragment reaction" 
experiments (Monro and Marcker 1967), the efficiency of pep­
tidyl transfer correlates with the chemical structure of the 
donor amino acid residue (Krayevsky and Kukhanova 1979; 
Chladek and Sprinzl 1985), which structurally an functionally 
corresponded to the C-terminal amino acid of the nascent pep­
tide. The termination of translation may be influenced by the 
protein's last two amino acids. Lysine is found more fre­
quently at the C-termini of proteins in which ORF is termi­
nated at UAA, while a similar position is occupied more often 
by phenylalanine, or serine in case of the UGA stop codon 
(Arkov et al. 1993). Issakson and co-workers (Mottagui-Tabar 
et al. 1994) demonstrated that the frequency of read-through of 
UGA and UAG termination codons depends on the penulti­
mate amino acid. Thus, the C-terminus of nascent peptides 
may be involved in the fine tuning of protein synthesis. 
Nascent peptide interactions outdoors 
In many (and maybe all) of the cases discussed above, newly 
synthesized peptide may exert its effect on translation while 
still located within the ribosome. However, interaction of the 
nascent peptides with external factors "outside" of the ribo­
some is also known to play a role in regulation of translation. 
Signal recognition particles (SRP), involved in protein tar­
geting to the endoplasmic reticulum, interact with leader 
regions of the nascent polypeptides and stop or slow down 
translation until the peptide signal sequence is inserted into 
the membrane (Wolin and Walter 1988). Other factors that 
can also interact with leader regions of nascent peptides 
might control the process of protein synthesis by analogy 
with SRP (Wiedmann et al. 1994). Interaction of nascent 
peptides with external factors (chaperones, membranes, etc.) 
may be used to optimize the translation rate and to allow the 
nascent peptide time to fold into proper configuration. For 
example, it has been suggested that temporal arrest of the 
chloroplast protein D1 translation (the mechanism of which 
remains unknown) provides additional time for the nascent 
peptide chain to bind cofactors, such as chlorophyll, before 
the release of the protein from the ribosome (Kim et al. 
1994). 
An interesting example of cotranslational interaction of 
the nascent peptide with external factors outside of the ribo­
some comes from the studies of regulation of ß-tubulin syn­
thesis. Increased concentration of free ß-tubulin subunits in 
the cell triggers the degradation of ß-tubulin mRNA in poly­
somes (Cleveland 1989). The four N-terminal amino acids of 
ß-tubulin nascent peptide (MREI) are essential for such auto-
regulation (Yen et al. 1988;Backurskietal. 1994). When this 
segment of the nascent peptide is blocked by antibodies, the 
tubulin-dependent autoregulation is prevented, suggesting 
that binding of additional factors (possibly, free ß-tubulin 
subunits) to the nascent peptide N-terminus is necessary for 
mRNA degradation (Theodorakis and Cleveland 1992). 
Discussion 
Screening a random rRNA fragment library revealed the pres­
ence of clones that became erythromycin resistant of a result 
of expression of a pentapeptide encoded in 23S rRNA. Our 
current ideas of the mode of the e-peptide action are based on 
several experimental facts: (/) a short ORF in the E. coli 23S 
rRNA can be translated in vivo and in vitro (at least, from an 
rRNA fragment); (ii) translation of the e-peptide ORF in vivo 
makes cells resistant to low concentrations of erythromycin; 
(hi) similarly, translation of the e-peptide ORF in vitro 
decreases erythromycin sensitivity of the cell-free translation 
system; (;'v) in vitro translated peptide remains associated with 
the ribosome; (v) synthetic peptide, present in millimolar con­
centration, inhibits cell-free translation and peptidyl trans­
ferase reaction catalyzed by the ribosome; the latter effect is 
counteracted by erythromycin present at 100 uM concentra­
tion. Several assumptions are based on these facts: (i) ribo­
some is the target of the e-peptide action; (ii) translated 
peptide remains associated with, and acts on, the ribosome on 
which it has been synthesized; (iii) the peptide bound to the 
ribosome may affect its function. 
One of the key questions is the location of the e-peptide 
binding site. Our current model is that the e-peptide remains 
associated with the nascent peptide channel in the vicinity of 
the peptidyl transferase center and that when bound there the 
peptide can modulate ribosome function. This possibility 
emerges from comparison of the e-peptide with other c«-act-
ing peptides discussed in the previous paragraphs. It is likely 
that many of these peptides affect the ribosome while they are 
still bound to the nascent peptide channel. This is evident for 
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the nascent regulatory peptides of the bacterial antibiotic resis­
tance operons. Translation of these peptides is not yet com­
plete when they cause ribosome pausing; therefore, the peptide 
must still be in the form of peptidyl-tRNA. These peptides are 
very small (see Fig. 3A) and the amino acid sequence of the 
peptide immediately adjacent to the putative stalling site is 
most important for the peptide action (Mayford and Weisblum 
1989; Lovett 1994). Thus the "affector" segment of the peptide 
must be located very close to the peptidyl transferase center. 
This conclusion is corroborated by the fact that synthetic pep­
tides corresponding to the active portion of the cat and cm/A 
leader peptides can inhibit peptidyl transferase reaction in 
vitro, and this effect can be counteracted by erythromycin (Gu 
et al. 1993, 19946). The e-peptide is reminiscent of the cat, 
cmlA, and erm leader peptides in its size and putative ci's-mode 
of action and also in that some in vitro effects found for those 
peptides can also be reproduced with the e-peptide. For exam­
ple, similar to cat and cm/A leader peptides, the synthetic e-
peptide was able to inhibit peptidyl transferase reaction when 
present at 1-2 mM concentration and this effect could also be 
abolished by erythromycin. Therefore, it is likely that all of 
these short cis-acting peptides may interact with the same site 
in the vicinity of the peptidyl transferase center, probably 
overlapping with the erythromycin binding site (which would 
also explain why expression of the e-peptide in vivo results in 
resistance to erythromycin). In general, it is possible that the 
ribosomal compartment "used" by short peptides, such as 
leader peptides of antibiotic resistance operons or e-peptide, 
may be also used by some other cw-acting peptides discussed 
in the previous section. In spite of the larger size of some of 
these peptides, their functional segment may be located close 
to the C-terminus and thus may "fit" into the postulated site. 
In the case of e-peptide, its size seems to be important for 
the functional interaction with the ribosome. A nonsense 
mutation in the C-terminal codon of the e-peptide ORF, which 
makes the peptide one amino acid shorter, as well as mutations 
in the natural stop codon of the e-peptide ORF, which make 
the translation product longer, abolish e-peptide-dependent 
erythromycin resistance. However, the sequence specificity of 
the proposed short peptide binding site on the ribosome is 
unclear. It appears that this site has certain sequence prefer­
ences but does not have strict sequence requirements. In our 
studies of the mechanism of eRNA34 action, a number of 
e-peptide mutants with partially altered amino acid sequences 
were generated. Surprisingly, many of these mutants conferred 
erythromycin resistance similar to wild-type e-peptide, and 
when the sequence of the e-peptide ORF in eRNA34 was com­
pletely randomized, 10 to 20% of the clones exhibited erythro­
mycin resistance (Fig. 3B). Therefore, it is likely that several 
different pentapeptides can produce functional effects similar 
to the e-peptide. Such sequence flexibility makes it difficult to 
determine if the presence of an active peptide gene in the 
rRNA is evolutionarily conserved. The e-peptide ORF can be 
found at the junction of domains II and III of the 23S rRNA in 
some bacteria, both Gram-positive and Gram-negative, but it 
is missing in others. Nevertheless, since amino acid sequence 
of the peptide is not strictly critical for its activity, other short 
open reading frames that are present in rRNAs of most organ­
isms may serve as a source of active e-peptide analogs. The 
absence of strict sequence requirement that we observe for the 
e-peptide was also evident for some other eis-acting peptides. 
Missence mutations that did not affect peptide function have 
been described for a number of those peptides and there is no 
apparent sequence similarity between the different peptides 
listed in Fig. 3A. It is important to note, however, that most 
e-peptide clones with randomized pentapeptide ORF 
remained sensitive to erythromycin, even though mutant 
eRNA was produced in relatively high amount in at least some 
of the clones. Accordingly, eRNA instability could not 
account for erythromycin sensitivity in these clones and most 
probably translated peptides were "inactive." Thus, not every 
pentapeptide can be "functional." 
The primary function of e-peptide remains illusive. As 
already mentioned, we favor the hypothesis that erythromycin 
resistance caused by the e-peptide is a side effect of its puta­
tive functional interaction with the ribosome. Usually, eis-act­
ing peptides function as translational repressors and many (if 
not all) of the effects discussed in the review section can be 
explained by the ribosome pausing or stalling on mRNA. It is 
tempting to speculate that e-peptide can produce a similar 
effect. This idea is supported by the fact that the e-peptide can 
inhibit protein biosynthesis in vitro by interfering with the 
peptidyl tranferase reaction. High peptide concentrations (in 
the millimolar range) required for the observed in vitro effects 
can be explained by the difference between co-translation 
placing of the e-peptide into its binding site versus binding of 
exogenous peptide. We do not know why the cell "needs" to 
encode the putative repressor of the ribosome activity in 
rRNA. It may potentially use this arrangement to inhibit trans­
lation under conditions unfavorable for cell growth, which are 
usually accompanied by ribosome degradation. Fragmenta­
tion of rRNA is clearly one way to make expression of the 
encoded e-peptide possible. 
It should be noted that it remains yet unknown if e-peptide 
can be translated from intact 23S rRNA. The Shine-Dalgarno 
region of the e-peptide open reading frame is involved in sec­
ondary structure interactions in hairpin 46 (Egebjerg et al. 
1990) in intact 23S rRNA, and it is unlikely that under normal 
conditions it can be used efficiently for initiation of the e-pep-
tide translation. However, some spontaneous or engineered 
mutations in the 23S rRNA, which decrease stability of the 
hairpin, make expression of e-peptide possible (Douthwaite et 
al. 1985; T. Tenson and A. Mankin, in preparation). It is con­
ceivable that specific rRNA fragmentation or loosening of the 
hairpin structure, which may occur under certain physiologi­
cal conditions, can lead to the synthesis of e-peptide. In any 
event, occurrence in the rRNA of a gene whose product can 
act on the ribosome is, at the very least, highly suspicious and 
deserving of interest. 
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ABSTRACT A pentapeptide open reading frame equipped 
with a canonical ribosome-binding site is present in the 
Escherichia coli 23S rRNA. Overexpression of 23S rRNA 
fragments containing the mini-gene renders cells resistant to 
the ribosome-inhibiting antibiotic erythromycin. Mutations 
that change either the initiator or stop codons of the peptide 
mini-gene result in the loss of erythromycin resistance. Non­
sense mutations in the mini-gene also abolish erythromycin 
resistance, which can be restored in the presence of the 
suppressor tRNA, thus proving that expression of the rRNA-
encoded peptide is essential for the resistance phenotype. The 
ribosome appears to be the likely target of action of the 
rRNA-encoded pentapeptide, because in vitro translation of 
the peptide mini-gene decreases the inhibitory action of 
erythromycin on cell-free protein synthesis. Thus, the new 
mechanism of drug resistance reveals that in addition to the 
structural and functional role of rRNA in the ribosome, it may 
also have a peptide-coding function. 
Ribosomal RNA plays a fundamental role as a structural and 
functional component of the ribosome (1, 2). Because of its 
size and sequence complexity, rRNA also has considerable 
protein-coding capacity; indeed, relatively long open reading 
frames (ORFs) can be found in the rRNA of Escherichia coli 
and other organisms (3, 4). However, attempts to identify 
rRNA-encoded proteins in the cell have not been successful so 
far (5). Until now, the possible functional significance of the 
smaller ORFs in rRNA has been essentially ignored, even 
though biological activity of short peptides has been well 
documented (6-8). Furthermore, short peptides can modulate 
ribosomal activity (9—11), and peptide-like antibiotics are 
potent inhibitors of translation (12-14). In this paper we 
present experimental evidence that a pentapeptide mini-gene 
is present in E. coli rRNA; this mini-gene codes for a biolog­
ically active peptide capable of affecting ribosomal function. 
MATERIALS AND METHODS 
Strains, Enzymes, and Chemicals. E. coli strain JM109 was 
used in most experiments. E. coli strains 3000YA14 and CA161 
were obtained from the E. coli Genetic Stock Center Yale 
University. All restriction enzymes, Taq DNA polymerase, and 
T7 RNA polymerase were from Promega or New England 
Biolabs. Radioisotopes were from Amersham. MS2 RNA, 
pyruvate, pyruvate-kinase, and total E. coli tRNA were from 
Boehringer Mannheim; folinic acid was from Sigma; and glass 
fiber filters were from Fisher Scientific. The Met-Arg-Met-
Leu-Thr (MRMLT) and /V-formyl-Met-Arg-Met-Leu-Thr 
(fMRMLT) peptides were synthesized by TANA Bio-Systems 
(Houston) and Chiron (San Diego), respectively, and purified 
by HPLC. 
RNA Expression Vectors pPOTl and pPOT72. The RNA 
expression vectors pPOTl and pPOT72 were constructed on the 
base of the pGEX-2T plasmid (Pharmacia). The Tth\ll-BspM[ 
segment of the pGEX-2T plasmid was replaced with the Kpn 1 
linker to generate pGEX-K plasmid. A DNA fragment contain-
The publication costs of this article were defrayed in part by page charge 
payment. This article must therefore be hereby marked '*advertisement" in 
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ing sequences of the tac promoter (15), lac operator, Nhel cloning 
site, and trp terminator was introduced into the Kpnl site of 
pGEX-K to produce pPOTl vector (see Fig. IA). The transcripts 
originated at Ptac contain sequences of the lac operator and trp 
terminator at the 5'- and 3'-termini, respectively; these extra 
sequences form internal hairpins (see Fig. 15) and consequently, 
should not interfere with folding of the inserted rRNA fragments 
and may even increase the stability of the transcript (16, 17). 
Replacement of the pPOTl tac promoter with T7 RNA poly­
merase promoter and elimination of the upstream Kpnl restric­
tion site resulted in the generation of pPOT72 vector. When cut 
at the unique Kpnl site, pPOT72 can be used for in vitro run-off 
transcription of cloned rDNA fragments. The RNA transcripts 
generated in vitro from pPOT72 are almost identical to in 
WTO-generated transcripts from pPOTl (Fig. IB), except for the 
presence of several extra uridines at the 3'-end and three 
guanosines at the 5'-ends of the in vitro transcripts. 
Construction of the rRNA Random Fragment Library and 
Selection of Erythromycin-Resistant Clones. The complete E. 
coli rrn B operon was excised from the pKK3535 plasmid (3) as 
a 7.5-kb Bam HI fragment, circularized by overnight incuba­
tion with DNA ligase, and randomly fragmented by partial 
cleavage with DNAse I in the presence of Mn2+ (18). The 
resulting fragments, which ranged in size from «=30 bp to 
several hundred base pairs, were blunt-ended, ligated to the 
Spe 1 linkers, and cloned into the Nhel site of the pPOTl vector 
(neither Nhel nor Spel sites are present in the rrnB operon). 
About 104 clones were obtained after introducing the plasmid 
library into the E. coli JM 109 cells. 
To identify rRNA fragments which can render cells resistant 
to erythromycin, 5 X 104 library clones were plated onto agar 
plates containing 100 jug of ampicillin per ml, 1 mM isopropyl 
ß-D-thiogalactopyranoside (IPTG), and 150 fig of erythromy­
cin per ml. Eryr colonies that appeared on the plate after 24 
hr of incubation were grown in liquid cultures; plasmids were 
isolated and used to transform fresh cells. Phenotypes of the 
secondary transformants were tested by replica plating onto 
ampicillin (100 jig/ml)/erythromycin (150 ng/ml) and ampi­
cillin (100 /xg/ml)/erythromycin (150 ju.g/ml)/IPTG (1 mM) 
plates. Clones that showed IPTG-dependent Eryr phenotype 
("E-RNA" clones) were used for further analysis. 
Deletion Analysis of E-RNA. One of the initially selected 
E-RNA clones, expressing a fragment of the 23S rRNA gene 
spanning nucleotides 1233-1348, was subjected to deletion anal­
ysis. Deletions in rDNA were generated by PCR amplifying 
segments of the rDNA insert and reintroducing them into the 
pPOTl vector. Phenotypes of the cells transformed with deleted 
versions of the original clone were tested by replica plating on 
antibiotic-containing plates as described in the previous section. 
Introducing Mutations into E-RNA. To introduce random 
mutations into E-RNA, an oligodeoxyribonucleotide corre­
sponding to the 23S rRNA sequence 1234-1276, flanked by 
Spe 1 restriction sites, was synthesized so that all possible 
nucleotide substitutions were introduced at each position of 
Abbreviations'. IPTG, isopropyl-ß-D-thiogalactopyranoside. 
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the 23S rRNA sequence with a frequency of 1% (97% of the 
wild-type nucleotide). After synthesis of the second DNA 
strand and cleavage of the product with Spel, the double-
stranded DNA fragment was ligated into the Nhel site of the 
pPOTl vector. The recombinant plasmids were introduced 
into JM109 cells and clones exhibiting Ery5 or Eryr phenotypes 
were selected by replica plating. 
Fusion of the E-RNA Ribosome-Binding Site to the cat 
Reporter Gene. The cat gene was PCR-amplified from the 
pACYC 184 plasmid. The upstream PCR primer, CACTAGT-
GGAGGTATCAGAAGTGGAGAAAAAAATCAC, con­
tained the sequence of the ribosome binding site of the E-RNA 
mini-gene (underlined) and 15 nucleotides from the 5'-end of 
the cat gene starting from the second codon. The downstream 
PCR primer corresponded to the 3'-end of the cat gene. The 
PCR product was cut at the Spel sites present within the PCR 
primers and cloned into the Nhel site of the pPOTl vector. The 
resulting plasmid was introduced into JM109 cells, and the in 
vitro CAT assay was performed as described (19). 
Introduction of an Opal Suppressor tRNA Gene into E-RNA 
Clones. The gene of an opal suppressor tRNAArg with its own 
promoter was PCR-amplified from the pGFIBI plasmid (20) 
and introduced into the unique £co0109 restriction site (Fig. 
1 A) of recombinant pPOTl plasmids expressing wild-type or 
mutant E-RNAs corresponding to the 23S rRNA segment 
1234-1268. The plasmids were introduced into JM109 cells, 
and individual colonies were isolated and grown in liquid 
cultures containing 100 fig of ampicillin per ml. Cultures were 
diluted, and 20-fil aliquots containing »»20 and = 100 cells were 
spotted onto agar plates containing ampicillin (100 fig/ml)/ 
IPTG (1 mM) and ampicillin (100 fig/ml)/IPTG (1 mM)/ 
erythromycin (150 fig/ml) (21). Plates were incubated at 37°C 
16 hr for ampicillin/IPTG plates and 40 hr for ampicillin/ 
IPTG/erythromycin plates. 
In Vitro Translation. The rDNA segment (positions 1234— 
1268 in the 23S rRNA) was PCR-amplified from the recom­
binant pPOTl plasmid and inserted into the pPOT72 plasmid 
vector under the control of the T7 RNA polymerase promoter. 
The resulting plasmid was linearized by cutting with Kpnl and 
transcribed in vitro as recommended by the manufacturer of 
the T7 RNA polymerase (Promega). The RNA transcript was 
gel-purified and used in the cell-free translation system. 
Ribosomes and S100 enzyme fraction used in the cell-free 
translation system were prepared from the E. coli strain 
MRE600 as described previously (22). The preincubation step 
of the cell-free translation was carried out in a 50-/U.1 reaction 
mixture containing 8 mM MgCK, 80 mM KCl, 80 mM NH4CI, 
5 mM 2-mercaptoethanol, 20 mM Tris-HCl (pH 7.6), 1.5 mM 
ATP, 0.5 mM GTP, 5 mM pyruvate, 1.2 fig of pyruvate kinase 
per ml, 12 fig of folinic acid per ml, 1.2 mg of total E. coli tRNA 
per ml, 6 pmol of ribosomes (activated 5 min at 42°C), 90 fiM 
each of 19 amino acids (excluding phenylalanine), and 4 fil of 
the S100 fraction. The mixture was incubated with 10 pmol of 
phage MS2 RNA or with 10 pmol of in Wfro-transcribed 
E-RNA34 at 37° for 20 min. Eight microliters of erythromycin 
solution in 8 mM MgCl2/80 mM KC1/80 mM NH4C1/1.5 mM 
2-mercaptoethanol/20 mM Tris-HCl, pH 7.6 was added to the 
reaction mixture to bring erythromycin concentration to 0.4 or 
0.8 fig/ml, and the mixture was incubated 5 min at 37°C. This 
was followed by adding 42 /xl of a solution containing 8 mM 
MgCh, 80 mM KCl, 80 mM NH4C1, 1.5 mM 2-mercaptoetha­
nol, 20 mM Tris-HCl (pH 7.6), 1.8 mM ATP, 0.6 mM GTP, 6 
mM pyruvate, 1.4 fig of pyruvate kinase per ml, 14 fig of folinic 
acid per ml, 1.4 mg of total E. coli tRNA per ml, 107 fiM each 
of 19 amino acids (excluding phenylalanine), 60 fiM [3H]phe-
nylalanine [7.5 Ci/mmol (1 Ci = 37 GBq)], 10 pmol of phage 
MS2 RNA, and 4 fil of S100 fraction. The reaction mixture was 
incubated 20 min at 37°C. RNA was hydrolyzed by adding 200 
fil of 1M NaOH and incubating 10 min at 37°C. The synthe­
sized polypeptides were precipitated by adding 1 ml of 25% 
trichloroacetic acid/2% casamino acids and incubating 30 min 
on ice. Precipitates were collected in glass fiber filters; filters 
were dried and counted in a scintillation counter. 
RESULTS 
For studies of rRNA functions, an expression library of 
random rRNA fragments was prepared. Random fragments of 
the E. coli rrnB operon were inserted downstream of the strong 
tac promoter in the plasmid vector pPOTl (Fig. 1), and the 
resulting plasmid library was introduced into E. coli cells. 
About ten thousand clones were obtained which, upon induc­
tion of transcription from the tac promoter, generated rRNA 
fragments (or their complements) ranging in size from »=30 to 
500 nucleotides. The representation of rRNA sequences in the 
generated library appeared to be random; PCR analysis of the 
total library and sequencing of 20 randomly picked clones did 
not show predominance of any specific rRNA fragment. 
The library was screened for the presence of clones where 
expression of rRNA fragments increased cell resistance to 
ribosome-targeted antibiotics. A number of colonies appeared 
when cells were plated on agar medium containing erythro­
mycin. Erythromycin resistance was shown to be dependent on 
the presence of rDNA-containing plasmids rather than chro­
mosomal mutations, as Eryr phenotype of the selected clones 
cotransferred with the plasmids. Furthermore, transcription of 
a plasmid-borne rDNA segment was essential for erythromycin 
resistance, because transformed cells exhibited Eryr pheno­
type only in the presence of IPTG, an inducer of the tac 
promoter. The rRNA fragments produced in these clones were 
designated E-RNA for erythromycin resistance RNA. All the 
analyzed rDNA inserts from >20 different Ery' clones over-
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Fig. 1 Random rRNA fragment library. ( A )  The schematic map 
of the pPOTl plasmid vector. Relative location and orientation of the 
lacli and ß-lactamase (Apr) genes are shown by open arrows. An 
inducible tac promoter (P,ac) is shown by a black bar; lac operator 
(Oiac) and tryptophan terminator (T,rp) are shown by hatched bars; 
and transcription start site is shown by an arrow. The position of the 
£co0109 site used for introducing the suppressor tRNA gene is 
indicated. (B) The general secondary structure of the rRNA tran­
scripts expressed from the pPOTl library plasmids. rRNA segment of 
the transcript is represented by a zigzag line flanked by hairpins 
formed by the lac operator (Oiac) and trp terminator (T,rp) sequences. 
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FIG. 2. rRNA fragments ex­
pressed in the selected and con­
structed Eryr clones. The black 
bars shown under the schematic 
map of the rRNA operon corre­
spond to E-RNAs expressed in the 
originally selected Eryr clones. The 
bottom portion shows deletion 
analysis of the clone that expressed 
1233-1348 ^^^m 
1233-1305 —m m m m m m m m m  
1235-1299 
1235-1292 E-RNA corresponding to the 23S 
1235-1290 rRNA at positions 1233-1348. 
1235-1276 Filled bars correspond to the 
1235-1268 rRNA fragments that rendered 
cells resistant to erythromycin. 
Open bars represent fragments 
that did not confer erythromycin 
_ resistance. The scale at the bottom 
1250 1270 1290 1310 1330 1350 ä . .. -,,c DMA usu corresponds to the 23S rRNA nu-
I I I I I I I I I I I I meration (23). 
lapped in the region corresponding to positions 1233-1348 of 
the 23S rRNA (Fig. 2). In all the clones, the inserts were 
present in the direct orientation so that their transcription 
should result in production of sense 23S rRNA fragments. The 
smallest of the E-RNAs in the selected Eryr clones corre­
sponded to a 116-nt long segment of the 23S rRNA; subse­
quent deletion analysis showed that expression of an rRNA 
fragment only 34 nt long (E-RNA34), corresponding to the E. 
u G-C° 
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* GUG CGA AUG CUG ACA UAA GÜA 
Met Arg Met Leu Thr Stop 
MRMLT 
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MRMPT 
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FIG. 3. E-RNA mutants. { A )  The nucleotide sequence and secondary structure of the E. coli wild-type 23S rRNA segment encoding the 
pentapeptide mini-gene. The minimal rRNA fragment capable of conferring erythromycin resistance (E-RNA34) is shown in boldface. 
Shine-Dalgarno region (24) of the pentapeptide gene is boxed, and the sequence of the encoded peptide is indicated. (B) E-RNA mutants that 
retained ("active") or lost ("inactive") their ability to confer erythromycin resistance. Nucleotides identical with the wild-type rRNA are indicated 
by dashes; deletions arc marked by "X." Positions corresponding to the initiation codon and stop codon of the pentapeptide gene are outlined by 
vertical lines. (C) Amino acid sequences of the peptides that can be expressed from the wild-type and mutant E-RNA. 
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w.t. GGAGGUAUCAGAA GUG CGA AUG CUG ACA UAA GUA 
OGA mutant GGAGGUAUCAGAA GUG BGA AUG CUG ACA UAA GUA 
COG mutant GGAGGUAUCAGAA £UG CGA AUG CUG ACA UAA GUA 
CUG mutant 
AMPICILLIN /ERYTHROMYCIN 
CUG mutant 
Fig. 4. Effect of the opal suppressor TRNA on activity of wild-type and mutant E-RNA34. (A) Sequences of the wild-type E-RNA34 and CUG 
and UGA mutants. (B) Effect of erythromycin on growth of cells expressing wild-type and mutant E-RNA34 in the absence or in the presence 
of the opal suppressor tRNAAr®. Strains that were transformed with the wild-type or mutant E-RNA plasmids containing the suppressor tRNA^e 
gene are marked "sup." Diluted cell cultures were spotted on plates containing 1(H) fig of ampicillin per ml and 1 mM IPTG (left) or 100 fig of 
ampicillin per ml, 150 fig of erythromycin per ml, and 1 mM IPTG (right). The level of suppression caused by the suppressor tRNAAr« is -20% 
(19), which accounts for the smaller size of the colonies produced on erythromycin plates by cells expressing the UGA mutant of E-RNA34. 
coli 23S rRNA sequence between positions 1235 and 1268, 
could render cells resistant to erythromycin (Fig. 2). 
To get insights into the mechanism of E-RNA action, muta­
tions were introduced randomly into the structure of the E-RNA 
(Fig. 35). Distribution of mutations that abolished E-RNA 
activity revealed two critical regions: GUG at positions 1248-
1250 and UAA at positions 1263-1265. Remarkably, these two 
segments corresponded to initiator and terminator codons of a 
pentapeptide ORF present in E-RNA (Fig. 3/4). Moreover, a 
canonical Shine-Dalgarno sequence, GGAGGU (positions 
1235-1240), which is essential for initiation of translation in 
prokaryotes (24), is present seven nucleotides upstream from the 
initiator codon, at the 5'-end of E-RNA, and is important for its 
function, because deletion of GGAG (positions 1235-1238) ren­
ders E-RNA inactive (Fig. 2). These results raised the possibility 
that expression of a 23S rRNA-encoded pentapeptide Met-Arg-
Met-Leu-Thr (E-peptide) may be required for the observed 
erythromycin resistance in recombinant clones. 
To verify that the putative ribosome binding site of the 
E-peptide mini-gene could direct initiation of translation, the first 
16 nucleotides of E-RNA34, comprising the putative Shine-
Dalgarno sequence and the initiator GUG codon, were fused to 
the second codon of the chloramphenicol acetyltransferase re­
porter gene. Cells, transformed with the resulting chimeric con­
struct, became resistant to chloramphenicol and significant chlor­
amphenicol acetyltransferase activity was detected in the cell 
extracts (data not shown). This result confirmed that the putative 
ribosome binding site of the pentapeptide mini-gene present in 
the E. coli 23S rRNA can be efficiently used for initiation of 
translation. To directly test whether translation of the E-peptide 
mini-gene was required for erythromycin resistance, we investi­
gated whether function of an E-RNA with a nonsense mutation 
in the peptide ORF can be restored in the presence of a 
suppressor tRNA. We used E-RNA34 mutant, in which E-RNA 
function was abolished by a nonsense mutation in the second 
codon of the mini-gene, which converted the arginine codon 
CGA into the opal stop codon UGA (see Fig. 4). As a negative 
control, we used another inactive E-RNA mutant with a mutation 
in the initiator codon (CUG mutant, Fig. 4). A gene of the opal 
suppressor tRNA'"'« (20), expressed from its own promoter, was 
introduced into the same plasmid, and phenotypes of the trans­
formed cells were assessed by their plating on antibiotic-
containing agar plates (Fig. 4). Presence of the suppressor 
tRNA^8 restored ability of the UGA mutant, but not the CUG 
mutant, to confer resistance to erythromycin, thus proving that 
synthesis of the rRNA-encoded E-peptide was necessary for drug 
resistance. 
Effects of the E-peptide and E-RNA on translation apparatus 
was studied in the cell-free translation system. The synthetic 
E-peptides, MRMLT and f-MRMLT, did not influence eryth­
romycin sensitivity of in vitro protein synthesis up to 1 mM of the 
peptide concentration (data not shown). Yet, when E-RNA was 
added to the cell-free system, instead of the E-peptide, a repro­
ducible protection against erythromycin was observed (Fig. 5). 
Without the E-RNA, translation of the phage MS2 RNA was 
reduced =»3-fold in the presence of 0.4-0.8 jig of erythromycin 
per ml. If, however, ribosomes were allowed to translate E-RNA 
before addition of the phage RNA 'hen residual protein synthesis 
in the presence of erythromycin was ^2-fold higher. Because 
E-RNA reduces the effects of erythromycin not only in vivo but 
also in vitro, the translation apparatus appears to be a likely target 
of action of the rRNA-encoded peptide. 
DISCUSSION 
In this paper we demonstrated that production of specific rRNA 
fragments can render cells resistant to erythromycin. The rRNA 
sequences that conferred resistance were identified using an 
expression library of random rRNA fragments. This approach has 
considerable potential for isolating rRNA fragments with specific 
functions, because phenotypic selection makes it possible to 
screen thousands of clones expressing different rRNA fragments 
in a quest for sequences that can confer selectable phenotypes. 
In our selection, we used the ribosome-targeted antibiotic 
erythromycin as a selective agent. Erythromycin has a single 
binding site located on the large ribosomal subunit. Bound 
erythromycin protects positions A2058, A2059, and G2505 in 
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the central loop of domain V from chemical modification (25, 
26). Mutations in the same region result in Eryr phenotype 
(27-29). Adenine, corresponding to A2058 of the E. coli 23S 
rRNA, is methylated in the erythromycin producer, Strepto-
myces erythreus, rendering the ribosomes of the producer 
resistant to the drug; methylation of the similar position in the 
rRNA of E. coli and other bacteria prevents binding of 
erythromycin (30). Thus, there is ample experimental evidence 
suggesting that the primary binding site of erythromycin 
involves domain V of the 23S rRNA. Much to our surprise, the 
clones isolated from our library expressed E-RNAs derived 
from a different region of the 23S rRNA, the junction of 
domains II and III. The mode of E-RNA action began to 
emerge when mutations that affected initiator or terminator 
codons of the pentapeptide mini-gene present within E-RNA 
abolished resistance; this suggested that E-RNA action may be 
mediated by the expression of the rRNA-encoded E-peptide. 
The idea was corroborated by the observation that the ribo­
some binding site of the E-peptide mini-gene, fused to a 
reporter gene, could be efficiently used for initiation of 
translation. The final confirmation of this hypothesis was 
received from an experiment in which activity of an E-RNA 
with a nonsense mutation in the E-peptide gene was restored 
in the presence of a suppressor tRNA (Fig. 4). This clearly 
demonstrated that translation of E-RNA was required for 
erythromycin resistance of the E-RNA-expressing clones. 
Translation of E-RNA solved the problem of its relatively 
low abundance. At the initial stages of our experiments, we 
noticed that the amount of E-RNA accumulated in Ery' clones 
was relatively low, <1 mol % of the amount of 5S rRNA (data 
not shown), and was not enough to directly affect a significant 
portion of the ribosome population or to sequester a substan­
tial amount of intracellular erythromycin. Translation of E-
RNA resolves this contradiction, because multiple E-peptide 
molecules can be translated from one molecule of E-RNA. 
The mutational analysis revealed some functionally impor­
tant structural features of the E-peptide (Fig. 35). Conversion 
of the mini-gene's stop codon into a sense codon abolished the 
peptide-mediated erythromycin resistance suggesting that the 
presence of extra sequences at the C-terminus of the E-peptide 
is unfavorable for its activity. The importance of the transla­
tion termination site was also evident from the fact that the 
E-RNA mutant, in which the stop codon of the E-peptide 
mini-gene was changed from ochre UAA to amber UAG, 
remained active in the E. coli strain 3000YA14 but not in the 
isogenic strain CA161 (31) that carried an amber suppressor 
mutation (data not shown). The necessity for efficient termi­
nation of E-peptide translation suggests that the size of the 
E-peptide is essential for its activity. In contrast, the primary 
structure of the E-peptide appears to be less strictly con­
strained; whereas certain amino acid changes were deleterious 
for the E-peptide function (see "inactive mutants" in Fig. 35), 
the majority of missense mutations did not eliminate activity 
of E-RNA. Analysis of a bigger collection of E-peptide se­
quence variations should help to elucidate E-peptide sequence 
constraints (Tenson and Mankin, unpublished data). 
How can expression of a short peptide make cells resistant 
to an antibiotic? In general, E-peptide can sequester erythro­
mycin into an inactive complex, decrease uptake of the drug, 
or prevent its binding to the ribosome. To examine these 
possibilities, we studied effects of the E-peptide and E-RNA 
on cell-free translation. In vitro translation of the MS2 phage 
RNA is inhibited by micromolar concentrations of erythro­
mycin. Addition of up to 1 mM of the synthetic E-peptide 
(Met-Arg-Met-Leu-Thr or W-formyl-Met-Arg-Met-Leu-Thr) 
to the cell-free translation system did not reduce erythromycin 
inhibition. This ruled out direct sequestering of the drug by the 
E-peptide, because the peptide concentration was three orders 
of magnitude higher than that of the drug. However, when the 
in Wfro-transcribed E-RNA was present instead of E-peptide, 
the erythromycin effect was notably tjiminished. This effect 
was most prominent when ribosomes could translate E-RNA 
before the addition of a reporter cistron (phage MS2 RNA). 
In experiment, shown in Fig. 5, the ribosomes were preincu­
bated with either E-RNA or, in the control, MS2 RNA, in the 
presence of 19 amino acids (excluding phenylalanine). Under 
these conditions, =3 pmol of E-peptide is translated from 
E-RNA (data not shown), corresponding to one-half of the 
molar amount of the ribosomes present. After preincubation, 
an excess of MS2 RNA was added to the reaction mixture 
accompanied by 3H phenylalanine; because E-peptide does 
not contain phenylalanine, the label is incorporated only into 
the MS2 RNA-coded proteins. Fig. 5 shows that the ribosomes 
that were allowed to translate E-RNA became less sensitive to 
erythromycin, whereas erythromycin sensitivity of the ribo­
somes preincubated with MS2 RNA or without mRNA did not 
change (Fig. 5). It should be noted that a seemingly small effect 
of E-RNA on the erythromycin sensitivity of the cell-free 
protein synthesis can easily translate into a 3- to 4-fold increase 
of the drug's minimal inhibitory concentration observed when 
E-RNA is expressed in vivo (27). Because direct sequestering 
of erythromycin was ruled out in experiments with the syn­
thetic peptide and drug transport does not affect a cell-free 
system, the results of in vitro translation experiments suggest 
that the ribosome is a likely target of action of the E-RNA-
encoded E-peptide. One possible model is that the E-peptide 
remains tightly associated with the nascent peptide channel of 
the ribosome and hinders binding of erythromycin; this model 
is compatible with the known mode of erythromycin action 
(12,13,32,33). An interesting consequence of the model is that 
E-peptide should be placed into its target site cotranslationally 
and function in eis, affecting erythromycin sensitivity of the 
ribosome on which it has been translated. This suggestion is 
consistent with the observation that exogenously added syn­
thetic E-peptide was not effective in the cell-free system at 
physiological concentrations; the site of cotranslational place­
ment of functionally active peptide may be inaccessible for 
binding a peptide from the solution. Similar conclusions can be 
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drawn from the results of Lovett and coworkers (9, 10), who 
have shown that surprisingly high concentration of synthetic 
peptides were required to reproduce in vitro the effects of 
cis-acting peptides involved in translation attenuation. 
In our experiments, E-peptide was translated from a rRNA 
fragment expressed from a strong plasmid promoter. It is unclear 
yet whether E-peptide is expressed naturally. In the intact ribo­
some, the peptide mini-gene apparently remains cryptic because 
its ribosome-binding site is sequestered in the rRNA secondary 
structure (Fig. 14). As is evident from our results, the E-peptide 
expression can be activated by a specific RNA fragmentation. 
Cutting of the rRNA in the apex stem-loop of the helix at 
positions 1198-1247 of the 23S rRNA which may happen, for 
example, under conditions of physiological stress, can generate 
translatable rRNA fragments leading to production of the E-
peptide. Mutations are yet another way to activate expression of 
the rRNA-encoded E-peptide. A spontaneous deletion of 12 
nucleotides (positions 1219-1230) from the 23S rRNA gene has 
been described as causing resistance to erythromycin (34). The 
effect of this deletion in domain II was difficult to reconcile with 
the known location of the erythromycin-binding site in domain V 
of the 23S rRNA Our results offer a new explanation for the 
erythromycin resistance caused by deletion in domain II. The 
12-nt deletion destabilized the hairpin at positions 1198-1247, 
thus making the ribosome-binding site of the E-peptide mini-
gene more accessible and activating E-peptide expression. Anal­
ysis of effects of other deletions and nucleotide substitutions in 
the hairpin at positions 1198-1247 on erythromycin resistance 
strongly supports our explanation (35). 
In the absence of direct evidence for expression of E-peptide 
in normal cells, we can only speculate about its biological signif­
icance. It is not clear whether the presence of a functional peptide 
gene in rRNA is a suspicious coincidence or a result of evolu­
tionary selection. At the very least, the fact that the rRNA-
encoded peptide can affect translation raises a possibility that 
such arrangement can be used by the cell. Erythromycin resis­
tance is probably not a primary activity but a side effect of 
interaction of the rRNA-encoded peptide with the ribosome. 
Similar to other peptides that can affect the function of the 
ribosome in eis, the E-peptide may be involved in regulation of 
translation (36-38); in this case it is expected to be expressed only 
under certain conditions that are compatible with the cryptic 
nature of the E-peptide gene in the intact 23S rRNA 
It is worth noting that E-peptide effects were not restricted to 
a particular E. coli strain. Thus, strains DH5a, JM109, and 
HB101, which significantly differ in their erythromycin sensitivity, 
all exhibited E-peptide-dependent erythromycin resistance. All 
the tested strains, upon transformation with the E-RNA-
expressing plasmid, could tolerate erythromycin concentration 2 
to 3 times higher than the respective minimal inhibiting concen­
trations. Because translation apparatus is extraordinarily con­
served, it is expected that ribosomes of other bacteria may also 
exhibit erythromycin resistance upon interaction with the E-pep­
tide or its analogs. Therefore, it is possible that some cases of 
erythromycin resistance observed in clinical isolates can be due 
to mutations in the rRNA genes activating expression of the 
E-peptide. Such a mutation, even in one of multiple rRNA gene 
copies, is expected to be dominant; ribosomes expressed from the 
wild-type rRNA genes would become resistant due to interaction 
with E-peptide translated from the mutant rRNA. Many, but not 
all, prokaryotic 23S rRNA sequences contain a pentapeptide 
mini-gene at the junction of domains II and III. However, it might 
well be that functional peptides are encoded in other short ORFs 
which are found in rRNA of practically all organisms. It would be 
also interesting to analyze whether expression of other short 
peptides, not necessarily encoded in rRNA could contribute to 
appearance of bacterial strains resistant to low erythromycin 
concentrations. 
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COMMUNICATION 
Mutations in Domain II of 23 S rRNA Facilitate 
Translation of a 23 S rRNA-encoded Pentapeptide 
Conferring Erythromycin Resistance 
Mette Dam1, Stephen Douthwaite1, Tanel Tenson2 and 
Alexander S. Mankin2* 
Mutations in domain II öf Escherichia coli 23 5 rRNA that cause resistance 
to erythromycin do so in a manner fundamentally different from mutations 
at the drug binding site in domain V of the 23 S rRNA. The domain II 
mutations are located in a hairpin structure between nucleotides 1198 and 
1247. This is close to a short open reading frame in the 23 S rRNA that 
encodes a pentapeptide (E-peptide). Whose expression in vivo renders cells 
resistant to erythromycin. Therefore, a possible mechanism of resistance 
caused by domain II mutations may be related to an increased expression 
of the E-peptide. To test this hypothesis, a range of point mutations was 
generated in domain II of 23 S rRNA in the vicinity of the E-peptide open 
reading frame. We find a correlation between erythromycin resistance of 
the mutant clones and increased accessibility of the ribosome binding site 
of the E-peptide gene. Furthermore, the erythromycin resistance 
determinant in the mutants Was shown to be confined to a small 23 S rRNA 
segment containing the coding region and the ribosome binding site of the 
E-peptide open reading frame. It thus appears that the domain II mutations 
mediate erythromycin resistance by increasing expression of the 23 S 
rRNA-encoded E-peptide. 
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Erythromycin is a potent inhibitor of bacterial 
protein synthesis, and is thought to act by sterically 
hindering growth of the nascent peptide chain 
(Vazquez, 1979). The binding site for erythromycin 
is located on the large ribosomal subunit in the 
vicinity of the peptidyl transferase center. Most of 
the rRNA nucleotide alterations that cause ery­
thromycin resistance are point mutations and base 
methylation within the central loop of domain V of 
the 23 S rRNA (for reviews see Weisblum, 1995; 
Garrett & Rodriguez-Fonseca, 1995; and see 
Figure 1). Several nucleotides in this region are 
protected by erythromycin from chemical modifi-
Permanent address: T. Tenson, Institute of Molecular 
and Cellular Biology, Tartu University, Tartu, Estonia. 
Abbreviations used: ORF, open reading frame; S.D., 
Shine-Dalgarno sequence; E-peptide; 23 S 
rRNA-encoded pentapeptide, 1200-1250 hairpin, a 
region of the E. coli 23 S rRNA secondary structure 
encompassing positions 1198 to 1247; IPTG, 
isopropyl-ß-thiogalactopyranoside. 
cation (Moazed & Noller, 1987). This internal loop 
in domain V of the 23 S rRNA thus appears to be 
the primary binding site for erythromycin. 
It was therefore surprising that a mutation in 
another region of the 23 S rRNA was also shown to 
confer erythromycin resistance (Douthwaite et al., 
1985). Deletion of 12 nucleotides (positions 1219— 
1230) within a conserved rRNA hairpin structure 
between nucleotides 1198 and 1247 (the 1200-1250 
helix) in domain II of the Escherichia coli 23 S rRNA 
gene, increased the minimal concentration of 
erythromycin required to inhibit cell growth three 
to four times. Other engineered deletions in this 
region produced similar effects (Douthwaite et al., 
1989). Curiously, however, these deletions did not 
affect binding of erythromycin to the mutant 
ribosomes, as assayed by footprinting in vitro 
(Douthwaite et al., 1989). This contrasts with a 
marked reduction in the ribosome-drug interaction 
caused by point mutations at the central loop in 
domain V (Douthwaite & Aagaard, 1993). These 
observations were taken to indicate that the deletion 
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Figure 1. The outline of the 23 S 
rRNA secondary structure (Noller, 
1984; Gutell et al., 1994). The 1200-
1250 hairpin in domain II is shown 
in bold. 
mutations disrupted a functional interaction be­
tween domains II and V, and thereby suppressed 
the action of the drug without preventing its 
binding. However, these observations can now be 
reinterpreted in the light of new data. 
Recently, a novel type of erythromycin resistance 
has been proposed, the mechanism of which is 
based on interaction between a specific pentapep­
tide and the ribosome (Tenson & Mankin, 1995; 
Tenson et al., 1996). This peptide (the E-peptide) is 
encoded in a short open reading frame (ORF) 
between nucleotides 1248 and 1265 at the junction 
of domains II and III within the E. coli 23 S rRNA 
(Figure 2). A putative Shine-Dalgarno region (S.-D.; 
Shine & Dalgarno, 1974) for the E-peptide ORF is 
located at the adjacent sequence 1235 to 1240. The 
proximity of this ORF to the position of the domain 
II deletions suggests that resistance to erythromycin 
might be acquired, owing to enhanced expression of 
the E-peptide. Here we present data on a range of 
point mutations that have been introduced into the 
1200-1250 helix. These mutations reduce the 
stability of the helix and render the putative S.-D. 
sequence more accessible. By correlating the 
accessibility of the S.-D. sequence with cell 
resistance to erythromycin, we are able to test the 
E-peptide hypothesis. 
Effects of helix 1200 to 1250 mutations in 
intact 23 S rRNA 
The E-peptide ORF has a canonical S.-D. 
sequence. In the intact 23 S rRNA, this S.-D. 
sequence is a part of the 1200-1250 hairpin struc­
ture (Figures 1 and 2; and Noller, 1984), and is 
presumably unavailable to serve as a ribosome 
binding site for initiation of translation. Nucleotide 
substitutions were generated in the 1200 to 1250 
hairpin to investigate whether altering the stability 
of the hairpin gives rise to erythromycin resistance. 
The mutant 23 S rRNAs were expressed in vivo from 
the multicopy plasmid pLK55, which contains a 
complete rRNA operon under the control of the 
lambda PL promoter. Some of the point mutations 
notably increased cell tolerance to erythromycin 
(Table 1). To rationalize the effects of individual 
mutations, the stability of the 1200-1250 hairpin in 
the mutant 23 S rRNAs was calculated. These 
results are presented in Table 1, and some of the 
representative secondary structures are shown in 
Figure 2. 
The data reveal a strong inverse correlation 
between the stability of the 1200-1250 hairpin and 
the drug resistance of cells. Out of 35 analyzed 
mutants only two, pLK55-130 and -136, do not 
follow this general rule. Mutants 130 and 136 are 
erythromycin-sensitive, although the over-all stab­
ility of the mutant hairpin is weakened (AG = -8.9 
and -6.5 kcal/mol, respectively, compared to 
-15.4 kcal/mol for the wild-type helix). However, 
the 1206A mutation present in these mutants 
directly stabilizes the interaction between the S.-D. 
sequence and the opposite side of the hairpin, so 
that weakening of the apex part of the hairpin may 
be not sufficient to release the S.-D. region 
(Figure 3). In addition, the 1236A mutation in 
pLK55-136 changes the actual S.-D. sequence, 
reducing its complementarity to the 3' end of 16 S 
rRNA. 
Several mutants carry a 1248A mutation, which 
changes the rarely used initiation GUG codon of the 
E-peptide ORF to the prevailing initiator codon 
AUG (Table 1). The change of initiator codon alone 
is not sufficient to significantly increase expression 
of the E-peptide, since mutant 11, having only the 
1248A mutation, remains erythromycin-sensitive. 
However, enhanced drug resistance is observed 
when the AUG initiator codon occurs in combi­
nation with mutations that increase the accessibility 
of the S.-D. region (mutant 48, Figure 2). The 
pLK55-48 construct exhibits the highest level of 
erythromycin resistance of all the point mutants 
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Figure 2. Putative secondary structure of the 1200-1250 helix in wild-type and mutant 23 S rRNAs. The wild-type 
(WT) structure is shown, together with the adjacent region encoding the E-peptide. The Shine-Dalgarno sequence and 
the initiator codon of the ORF are boxed. Putative RNA structures resulting from deletions are illustrated, and point 
mutations in the mutants pLK55-136 and -48 are circled. 
analyzed (Table 1). Hence, mutations that may 
increase expression of the rRNA-encoded E-peptide 
result in an Eryr phenotype, while those mutations 
that would either reduce or leave the peptide 
expression significantly unchanged do not confer 
drug resistance. 
A similar trend emerges on examination of 
deletion mutations that also affect the hairpin 
stability (Douthwaite et al., 1989). Comparison of 
the secondary structure in these mutants with the 
wild-type hairpin structure is more complicated, 
because in many cases the deletions will cause an 
Communication 
Table 1. Effect of point mutations on erythromycin resistance and stability of the 1198-1247 
hairpin 
Plasmid' Mutations Phenotypeb Hairpin AGC 
pLK55-29 1210A, 1218A, 1248A S -15.7 
pLK55 (w.t.) none S -15.4 
pLK55-l 1 1248A S -15.4 
pLK55-157 1235A S -15.4 
pLK55-152 1215A S -15.2 
pLK55-15 1206A S -15.1 
pLK55-114 1236A S -15.1 
pLK55-21 1227A, 1236A S -14.9 
pLK55-150 1218A, 1245A S -13.7 
pLK55-36 1225A S -13.4 
pLK55-79 1197 A, 1202A, 121 OA, 1250A S -13.4 
pLK55-246 1233U S -13.0 
pLK55-262 1208U S -12.8 
pLK55-248 1229U S 
-12.8 
pLK55-58 1238A S 
-12.8 
pLK55-232 1208U, 1211U S 
-12.6 
pLK55-204 1207U S -12.4 
pLK55-244 1221U, 1243U s -11.9 
pLK55-243 1208U, 1243U R35 -11.8 
pLK55-241 1207U, 1243U R35 -11.5 
pLK55-17 1232A, 1238A S -11.4 
pLK55-245 1221U, 1233U R50 -10.5 
pLK55-233 1221U, 1229U R35 -10.4 
pLK55-247 1200U, 1208U, 1221U R35 -9.4 
pLK55-130 1206A, 1228A S 
-8.9 
pLK55-45 1220A, 1239A R35 -8.9 
pLK55-138 1220A, 1223A, 1228A R50 -8.9 
pLK55-259 1200U, 1207U, 1208U. 1211U, 1221U R50 
-8.3 
pLK55-260. 1200U, 1207U, 1208U, 1211U, 1221U, 1243U R50 -8.3 
pLK55-212 1208U, 1221U, 1229U R50 -7.8 
pLK55-264 1206A, 1216A, 1218A, 1223A, 1232A, 1239A R50 -7.5 
pLK55-125 1202A, 1206A, 1212A, 1225A, 1228A, 1235A R35 -7.1 
pLK55-48 1216A, 1227A, 1228A, 1248A R80 -6.9 
pLK55-136 1206A, 1216A, 1228A, 1236A S 
-6.5 
pLK55-258 1208U, 1211U, 1221U, 1229U, 1233U, 1243U R50 -4.2 
"Mutations were generated in a 1 kb Sacl-Satl fragment of the 23S rRNA gene sub-cloned into 
bacteriophage M13. DNA heteroduplexes were formed in a manner similar to that described by Rosendahl 
& Douthwaite (1995), creating a single-stranded window at the sequence from 1197 to 1248. Mutations 
were introduced by bisulfite deamination of cytosine residues in the single-stranded window (Pine & 
Huang, 1987). Both strands of the gene fragment were mutagenized to give G -» A as well as C -» U 
transitions. Sacl-Sall fragments were cloned back into their original rniB context for expression from the 
lambda Pl promoter in pLK55. Plasmid pLK55 is essentially identical to pLK35 (described by Douthwaite 
et al., 1989) but contains a phenotypically neutral allele-specific priming site around 23 S rRNA position 
1360 (Aagaard et al., 1991). Plasmids pLK35 and pLK55 are pBR322 derivatives containing the entire E. 
coli miB operon under control of the lambda PL promoter (Gourse et al., 1985). Plasmids were propagated 
in the E. coli strain DH1 (Sambrook et al., 1989) for which minimal inhibitory concentration of 
erythromycin was 25 ng/ml. 
b Phenotype of the mutants was determined by plating on agar containing ampicillin at 25 (.ig/ml and 
different concentrations of erythromycin. S, erythromycin-sensitive mutants; R35, R50 and R80, mutants 
capable of growing in the presence of 35 ng/ml, 50(ig/ml and 80 ng/ml erythromycin, respectively. 
c Stability of the wild-type and mutant hairpins (kcal/mo!) was determined using energy minimization 
program (Zuker, 1994) provided on M. Zuker's world wide web homepage (http://ibc.wustl.edu/ 
~zuker/cgi-bin/forml.cgi). 
alternative folding of this RNA region. Neverthe­
less, there is generally a good correlation between 
accessibility of the S.-D. region of the E-peptide 
ORF and erythromycin resistance of the mutant. 
Small deletions that have little effect on hairpin 
stability do not induce erythromycin resistance (e.g. 
mutants A1223-1226 in Figure 2). However, a 
similar size deletion, which weakens the hairpin 
(mutant A1231-1234), produces an Eryr phenotype. 
Removal of more than four nucleotides significantly 
destabilizes the hairpin. Thus, mutants lacking 4 
to 11 nucleotides to the 3' side from position 1229 
are erythromycin-resistant (for example, mutants 
A1229-1234 and A1229-1236 in Figure 2). Longer 
deletions on this side of the helix (12 or more 
nucleotides 3' to position 1229) start to remove the 
S.-D. sequence resulting in loss of resistance. 
Deletions of 9 to 17 nucleotides 5' to the position 
1232 destabilize the hairpin, while leaving the S.-D. 
sequence intact and also confer drug resistance. All 
these observations are completely consistent with 
the prediction that an accessible S.-D. sequence is 
required for translation of the E-peptide. However, 
it is not immediately obvious why mutants carrying 
23 S rRNA lacking 17 to 24 nucleotides 5' to the 
position 1232 are not resistant to erythromycin. 
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• POT1192-1305 
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Figure 3. Erythromycin inhibition of cell growth. Cells 
transformed with an empty pPOT vector (A), or vector, 
expressing the 23 S rRNA fragment 1192-1305 (•) or the 
1235-1276 fragment (•) were grown overnight in LB 
medium containing ampicillin at 100 ng/ml. Samples 
(50 |il) of overnight cultures were inoculated into 2 ml LB 
medium containing ampicillin at 100 ng/ml, 1 mM IPTG 
and different concentration of erythromycin. Cultures 
were grown for 3.5 hours at 37°C with constant shaking, 
and the absorbance was measured at 600 nm. 
Possibly, the mutant rRNA folds up differently and 
prevents access to the E-peptide ORF S.-D. or, 
alternatively these deletions could enhance degra­
dation of the rRNA. In spite of these exceptions, the 
effects of the majority of Eryr point mutations and 
deletions can be explained by weakening the 
hairpin structure and making the S.-D. region of the 
E-peptide ORF more accessible. 
Small rRNA fragments derived from mutant 
23 S rRNA can confer erythromycin resistance 
The mechanism of erythromycin resistance 
conferred by domain II mutations was originally 
thought to involve a change in the 23 S rRNA 
function within the ribosome (Douthwaite et al., 
1985). If this were the case, intact mutant 23 S rRNA 
would be required for assembly into functionally 
active ribosomes. However, if our new model is 
correct and the Ery' effect of domain II mutations is 
mediated by translation of the E-peptide, the 
presence of the intact mutant 23 S rRNA would be 
unnecessary, and smaller rRNA fragments should 
be sufficient to confer resistance. 
As the first step to discriminating between the 
two models, the erythromycin tolerance of cells 
expressing the wild-type 23 S rRNA fragment 
1192-1305 (containing the complete 1200-1250 
hairpin) was compared with the tolerance of cells 
expressing the fragment 1235-1276 where only 3' 
strand of the hairpin was present. These rRNA gene 
pPOT 
• pLK 
CM CM 
Figure 4. Growth of cells expressing complete mutant 
23 S rRNA (open bars) or mutant rRNA fragments (black 
bars) in the presence of a subinhibitory concentration of 
erythromycin. Mutant 23 S rRNA was expressed from a 
multicopy pLK 55 plasmid under the control of lambda 
PL promoter. Fragments from positions 1192 to 1305 were 
PCR amplified from wild-type (w.t.) and mutant 23 S 
rRNA alleles and introduced into the pPOTl vector 
(Tenson et al., 1996), where they were expressed from the 
tac promoter. Wild-type and mutant rRNA fragments 
were expressed in approximately the same amounts as 
revealed by Northern blotting. All the plasmids were 
propagated in JM109 cells (Sambrook et al., 1989). Samples 
(10 (il) of overnight cultures were inoculated into 2 ml LB 
medium containing 100 ng/ml ampicillin and 1 mM IPTG 
with or without 100 (ig/ml erythromycin. (Minimal 
inhibitory concentration of erythromycin for untrans-
formed E. coli JM109 cells was 150 ng/ml). Cultures were 
grown for five hours at 37°C, and their absorbance at 
600 nm was measured. Growth of the cells in the presence 
of erythromycin was normalized according to their 
growth in the absence of erythromycin. 
fragments were PCR amplified from the E. coli rrn B 
operon and introduced into the pPOTl vector, 
where they were expressed under the control of 
IPTG-inducible tac promoter (Tenson et al., 1996). 
The cells expressing the 1235-1276 rRNA fragment 
exhibited significantly lower resistance to ery­
thromycin compared to the cells expressing 1192-
1305 fragment (Figure 3). This again indicates that 
expression of the E-peptide is prevented when the 
1200-1250 hairpin remains intact. 
Next, gene fragments of the mutant 23 S rRNAs, 
containing the entire 1200-1250 hairpin and 
E-peptide ORF, were expressed in vivo from the tac 
promoter of the pPOTl vector (Tenson et al., 1996). 
Cell growth in the presence of subinhibitory 
concentrations of erythromycin was measured. For 
the five mutations tested, a close correlation was 
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observed between their ability to confer ery­
thromycin resistance when expressed in the con­
text of intact 23 S RNA and in the context of small 
rRNA fragments (Figure 4). These results demon­
strate that the resistance determinant in the tested 
mutants is confined to the 23 S rRNA region 
containing the 1200-1250 hairpin and the adjacent 
E-peptide ORF, and thus provides further support 
to the hypothesis that erythromycin resistance is 
mediated by an increased expression of the 
E-peptide. 
Conclusions 
23 S RNA domain II deletions and point 
mutations that confer erythromycin resistance do so 
by a completely different mechanism than other 
Eryr mutations located at the drug binding site in 
domain V. Eryr mutations in domain II affect the 
stability of a hairpin in which the S.-D. region of the 
rRNA-encoded E-peptide ORF is sequestered. Since 
accumulation of the E-peptide affords erythromycin 
resistance (Tenson & Mankin, 1995; Tenson et al., 
1996), it is most probable that the effect of Eryr 
mutations in domain II is to mediate activation of 
expression of the E-peptide, which is apparently not 
translated from the intact wild-type 23 S rRNA. 
Furthermore, it is possible that the peptide-medi-
ated mechanism of erythromycin resistance ac­
counts for Ery' phenotypes of some clinical bacterial 
isolates. 
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Translation of a 5-codon mini-gene encoded in Esche­
richia coli 23 S rRNA was previously shown to render 
cells resistant to erythromycin (Tenson, T., DeBlasio, A., 
and Mankin, A. S. (1996) Proc. Natl. Acad. Sei. U. S. A. 93, 
5641-5646). Erythromycin resistance was mediated by a 
specific interaction of the 23 S rRNA-encoded pentapep­
tide with the ribosome. In the present study, peptides 
conferring erythromycin resistance were selected from 
in vivo expressed random peptide libraries to study 
structural features important for peptide activity. 
Screening of a 21-codon mini-gene library (the general 
structure ATG (NNN)20 TAA) demonstrated that only 
short peptides (3-6 amino acids long) conferred eryth­
romycin resistance. Sequence comparison of erythromy­
cin resistance peptides isolated from the 5-codon library 
(ATG (NNN)4 TAA) revealed a strong preference for 
leucine or isoleucine as a third amino afid and a hydro­
phobic amino acid at the C terminus of the peptide. 
When tested against other antibiotics, erythromycin re­
sistance peptides rendered cells resistant to other mac-
rolides, oleandomycin and spiramycin, but not to chlor­
amphenicol or clindamycin. Defining the consensus 
amino acid sequence of erythromycin resistance pep­
tides provided insights into a possible mode of peptide 
action and the nature of the peptide binding site on the 
ribosome. 
It was assumed for a long time that the ribosome is indiffer­
ent to the sequence of the polypeptide it is synthesizing. New 
evidence, however, indicates that nascent or newly synthesized 
polypeptides can affect functions of the ribosome in eis. In a 
number of cases, the newly translated peptide exerts its effect 
on translation while still being located within the ribosome. For 
example, short nascent peptides regulate stalling of the ribo­
some on mRNA, which is required for inducing the expression 
of chloramphenicol resistance (cat and cmlA) and erythromycin 
resistance (erm) genes (1, 2). Ribosome stalling depends on the 
amino acid sequence of the nascent peptide rather than on the 
nucleotide sequence of mRNA and occurs when the nascent 
peptide is only several amino acids long and should be located 
within the ribosome. Other examples include: translational 
bypass of the coding gap in bacteriophage T4 gene 60 mRNA 
(ribosome "hopping"), which depends on the amino acid se­
* This work was supported by National Institutes of Health Grant 
GM53762. The costs of publication of this article were defrayed in part 
by the payment of page charges. This article must therefore be hereby 
marked "advertisement" in accordance with 18 U.S.C. Section 1734 
solely to indicate this fact. 
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University, Tartu, Estonia. 
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ceutical Biotechnology-m/c 870, University of Illinois, 900 S. Ashland 
Ave., Chicago, IL 60607-7173. Tel.: 312-413-1406; Fax: 312-413-9303; 
E-mail: shura@uic.edu. 
quence of the nascent peptide (3); dependence of termination 
efficiency on the amino acid sequence of the nascent peptide (4); 
attenuation of eukaryotic gene expression by short upstream 
open reading frames, which depends on the encoded amino acid 
sequences but not the mRNA sequence; and others (5-7). De­
spite a growing number of cases where cis-action of the newly 
synthesized peptide on the ribosome has been either demon­
strated or suspected, almost nothing is known about molecular 
mechanisms of interaction between the ribosome and regula­
tory cis-acting peptides. The nature and location of the peptide-
responsive site remains obscure. 
A new example of a cis-acting peptide is represented by a 
pentapeptide encoded in Escherichia coli 23 S rRNA (6). It was 
demonstrated that production in E. coli cells of a 34-nucleotide-
long segment of 23 S rRNA, positions 1235-1268 (8), renders 
cells resistant to the ribosome-targeted antibiotic erythromycin 
(8, 9). Curiously, erythromycin resistance was mediated by 
translation of a pentapeptide (E-peptide)1 encoded in the rRNA 
fragment. Mutations that affected translation initiation signals 
of the E-peptide mini-gene (Shine-Dalgarno region and initia­
tor GUG codon) abolished erythromycin resistance. Interest­
ingly, mutations at the terminator UAA codon, as well as some 
missense mutations, also interfered with peptide activity, sug­
gesting that the size of the peptide and its amino acid sequence 
are essential for its functions. Translation of the E-peptide 
mRNA in the cell-free system rendered ribosomes resistant to 
erythromycin. However, addition of the synthetic E-peptide to 
the translating ribosome in vitro did not confer any erythromy­
cin resistance (8). Thus, it appears that the E-peptide acts in eis 
so that only the ribosome on which the peptide has been trans­
lated becomes resistant to the drug. The single binding site of 
erythromycin is located on the large ribosomal subunit in the 
vicinity of the peptidyltransferase center. Accordingly, one pos­
sible mechanism of the E-peptide action is that the newly 
translated peptide remains bound to the ribosome and occupies 
the erythromycin binding site, thus preventing drug binding. 
However, fundamental questions of how and where such inter­
action may occur remains unanswered. This is due in part to a 
lack of information about structural features of the E-peptide 
that are important for its function. 
To gain a better understanding of the size and sequence 
requirements for E-peptide activity, a library of in vivo ex­
pressed random peptides was constructed from which a collec­
tion of erythromycin resistance peptides was isolated. Compar­
ison of their sizes and sequences revealed structural features 
that are important for the activity of erythromycin resistance 
peptides and their interaction with ribosome. 
1 The abbreviations used are: E-peptide, erythromycin resistance 
pentapeptide; PCR, polymerase chain reaction; IPTG, isopropyl-l-thio-
ß-D-galactopyranoside; MIC, minimal inhibitory concentration. 
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EXPERIMENTAL PROCEDURES 
Strains and Materials—E. coli JM109 strain (10) (endAl, recAl, 
gyrA96, thi, hsdRll (rK~, mK*, relAl, s«pE44, A(lac-proAB)f [F', 
traD36, proAB, /acIqZDM15] was used for most of the cloning experi­
ments. For the library construction, the ligation mixtures were origi­
nally transformed into ultracompetent E. coli cells XL2-Blue MRF' 
(A(mcrA)183, A(mcrCB-/isdSMR-mrr)173, endAl, su/)E44, thi-1, rccAl, 
gyrA9G, relAX, lac [F' proAB, /ac/q, ZAM15, Tn20(tetr)] Amy, Camr) 
(Stratagene). Synthetic oligonucleotides were from DNAgency. En­
zymes were from Promega and New England BioLabs. Chemicals and 
antibiotics were from Fisher or Sigma. 
Library Construction — pPOTl vector described previously (8) was 
used for the construction of random peptide libraries. The original 
vector, which contains a Ptac promoter-Ti/p terminator expression 
cassette with a single Nhel cloning site, was modified by introducing 
sites for restriction nucleases EcoRI and Aflll between the Ptac pro­
moter and trp terminator. The resulting vector, pPOTlAE (see Fig. 1), 
was cut with £coRI and Aflll, and the linear plasmid was gel-purified. 
Random peptide mini-gene DNA was prepared from synthetic oligo­
nucleotides d(GGCTTAAGGAGGTCACATATG<N)12TAACTAGCTGA-
ATTCCG) or d(GGCTTAAGGAGGTCACATATG<N)60TAACTAGCTGA-
ATTCCG). The oligonucleotides were PCR-amplified from a pair of 
primers, d(CGGAATTCAGCTAGTTA) and d(GGCTTAAGGAGGTCA-
C). The PCR products were cut with JFcoRI and Aflll, gel purified, and 
ligated with linearized pPOTlAE vector. 
Plasmid libraries were transformed into E. coli XL2-Blue MRF' 
ultracompetent cells (Stratagene). An aliquot of transformed cells from 
each library was plated onto agar plates to estimate the number of 
clones in each library, whereas the rest of the cells were grown in 100 
ml of LB medium containing 100 /xg/ml ampicillin. When culture den­
sities reached AQQQ = 0.8, cells were harvested, and plasmid libraries 
were isolated. The 5- and 21-codon libraries contained —5 X 10s and 
~1 X 105 clones, respectively. 
Selection of Erythromycin Resistance Peptides ~E. coli JM109 com­
petent cells were transformed with the random mini-gene plasmid 
libraries and plated onto LB agar plates containing 100 /ig/ml ampicil­
lin, 150 /ig/ml erythromycin, and 1 mM IPTG. Plates were incubated 
overnight at 37 °C. Colonies that appeared on plates were streaked on 
plates containing 100 /xg/ml ampicillin and 150 /ig/ml erythromycin or 
100 /ig/ml ampicillin, 150 /ig/ml erythromycin, and 1 mM IPTG. Colo­
nies growing in the presence but not in the absence of IPTG were taken 
for further analysis. Plasmids were isolated from all selected clones and 
retransformed into fresh competent cells, and phenotypes of the sec­
ondary transformants were checked by replica plating onto ampicillin/ 
erythromycin or ampicillin/erythromycin/IPTG plates. Peptide mini-
genes from the plasmids conferring retransformable IPTG-dependent 
erythromycin resistance were sequenced. 
Selection of clones resistant to a higher concentration of erythromy­
cin was performed in essentially the same way except that the selective 
plate contained 1 mg/ml instead of 150 /ig/ml erythromycin. 
Comparing Erythromycin Resistance of Cells Expressing Different 
E-peptides—Overnight cultures of cells expressing different E-peptides 
were grown in LB medium containing 100 /ig/ml ampicillin. Cultures 
were diluted with LB medium containing 100 /xg/ml ampicillin and 2 
mM IPTG to the final density of = 0.005. 3 ml of each culture was 
placed into two 15-ml tubes, and tubes were incubated at 37° C with 
constant shaking. After a 1 h incubation, 10 /xl of erythromycin solution 
(30 mg/ml) was added to one of the two tubes in each parallel trial, and 
cells were grown until the optical density of the control cultures reached 
"~Ag5o — 1. At this time, optical densities of all cultures were measured. 
Absorbance of cultures grown in the presence of erythromycin was 
divided by the absorbance of cultures grown in the absence of erythro­
mycin, and the results were plotted. 
Testing Antibiotic Resistance of E-peptide-expressing Cells—Over­
night cultures were grown from cells transformed either with the empty 
pPOTlAE vector, a plasmid isolated from a randomly picked unselected 
clone expressing pentapeptide MDVEQ or a plasmid from Eiy clone 
expressing E-peptide MSLKV. Cultures grown in LB medium contain­
ing 50 /ig/ml ampicillin were diluted with fresh medium containing 50 
/xg/ml ampicillin and 1 mM IPTG to A600 = 0.008. Erythromycin, olean­
domycin, spiramycin, chloramphenicol, or clindamycin was then added 
to concentrations of 100, 1000, 200, 1, and 50 /xg/ml, respectively. 
Cultures were grown until optical density of the control culture, grown 
only in the presence of ampicillin and IPTG, reached A600 = 1. At this 
time, optical densities of all cultures were measured and normalized 
relative to the control culture. 
3CTTAAGGAGGTCACAT AIS (NNN)20 IÄA CTAGCTGAATTCf 
FIG. 1. A 21-codon mini-gene library in pPOTlAE vector. 
pPOTlAE is identical to the pPOTl vector described previously (8) 
except that Aflll and EcoRI cloning sites were introduced into a single 
cloning Nhel site of pPOTl. IPTG-inducible Ptac promoter is shown as 
a black bar, and the lac operator (Olac) and trp terminator (Ttrp) are 
shown as hatched bars. The transcription start site is indicated by an 
arrow. Aflll and EcoRI sites used for cloning of the mini-gene library 
are shown. The Shine-Dalgarno sequence (S.-D.), initiator AUG codon, 
and terminator UAA codon of the mini-gene are underlined. Positions of 
ß-lactamase gene (Apr) and lac Iq genes in the plasmid are shown by 
open arrows. 
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FIG. 2. Size distribution and amino acid sequences of erythro­
mycin resistance peptides isolated from the 21-codon library. A, 
distribution of peptide sizes (number of amino acids) encoded in mini-
genes in randomly picked unselected clones (open bars) and erythromy-
cin-resistant clones (shaded bars). The y axis represents the number of 
sequenced clones that encoded peptides of a particular size. B, amino 
acid sequences of peptides encoded in mini-genes in erythromycin-
resistant clones. Peptide sequences are aligned relative to the C-termi-
nal amino acid. 
Erythromycin Resistance Peptides 17427 
Construction of Random Mini-gene Libraries—Two random 
mini-gene plasmid libraries were constructed for isolation of 
peptides whose expression renders cells resistant to erythro­
mycin. Random mini-genes were generated by PCR amplifica­
tion of oligonucleotides containing initiator and terminator 
codons separated by 12 (for 5-codon library) or 60 (for 21-codon 
library) random nucleotides (Fig. 1). The initiator codon was 
preceded by an optimized Shine-Dalgarno sequence (11, 12) to 
ensure efficient translation of the mini-gene. The PCR-ampli-
fied mini-gene library was introduced unidirectionally in the 
pPOTlAE vector (8), where transcription of the mini-gene was 
controlled by a strong IPTG-inducible Pfac promoter. Sequenc­
ing mini-genes from a number of randomly picked unselected 
clones from both libraries showed no significant bias in nucle­
otide composition in the randomized segment of the mini-gene. 
The 5-codon library contained -500,000 clones. Since the total 
number of various pentapeptides (with fixed methionine in the 
first position) is 20* = 160,000, it was assumed that most 
possible pentapeptides were encoded in the 5-codon library. 
The 21-codon library had -105 clones. Naturally, only a rela­
tively small segment of the sequence space corresponding to all 
possible peptides encoded in 21-codon-long open reading 
frames were represented in this library. 
Isolation of Erythromycin-resistant Clones from 21-codon 
Random Mini-gene Library—Vae to an occasional presence of 
stop codons in a random open reading frame, the 21-codon 
library can encode peptides ranging in size from 1 to 21 amino 
acids. This library was used primarily to determine the pre­
dominant size of erythromycin resistance peptides. Clones that 
became erythromycin-resistant due to expression of peptide 
mini-genes were selected by plating the 21-codon library on 
agar medium containing ampicillin, erythromycin, and IPTG. 
For most clones that appeared on the plate, the Ery' phenotype 
was retransformable with the plasmid and depended on the 
presence of IPTG in the medium, indicating that expression of 
the peptide mini-gene was necessary for the resistance. Plas­
mids from 12 Ery' clones were sequenced alongside of plasmids 
isolated from several unselected, randomly picked clones. 
Whereas mini-genes in unselected clones showed a broad dis­
tribution of sizes of the encoded peptides (open bars in Fig. 2), 
the mini-genes in 12 isolated Ery clones encoded only short 
peptides in a very narrow range of sizes, from 3 to 6 amino acids 
(filled bars in Fig. 2). Thus, it appears that only short peptides 
can confer resistance to erythromycin. 
Erythromycin Resistance Peptides from 5-codon Mini-gene 
Library—The experiment with the 21-codon library showed 
that expression of predominantly short peptides can render 
cells erythromycin resistance. Furthermore, the first described 
erythromycin resistance peptide (E-peptide) is encoded in a 
5-codon-long open reading frame in the E. coli 23 S rRNA (8). 
Therefore, the next selection and all subsequent experiments 
were done with a plasmid library where random mini-genes 
contained only 5 codons. By analogy with the rRNA-encoded 
E-peptide, the erythromycin resistance pentapeptides selected 
from the library are referred to as E-peptides. 
More than 100 Eryr clones were selected from the 5-codon 
library on ampicillin/IPTG plates containing 150 /ig/ml eryth­
romycin. The relation of the Ery' phenotype to the expression of 
plasmid-encoded peptides was confirmed by IPTG-dependence 
of erythromycin resistance and by its co-transference with the 
plasmid. Peptide mini-genes from >50 Eryr clones were se­
quenced. Only 1 of these clones had an in-frame stop codon in 
the mini-gene that coded for a tetrapeptide MILV; pentapep­
tides were encoded in all the rest of the clones. Sequences of 
E-peptides expressed in Eryr clones showed significant devia-
: TTT TTG TAA 
; TTA TTG GTC GTG TAA 
; TGG TTA ATT TGG TAA 
; ATC CTT GGT GTT TAA 
; TAT CTT AAC ' 
i CGT TTG TGC J 
i GTT CTG GTG ( 
! CTG TTG TTG < 
; CTG TTG CTG C 
I CTG CTA TTG C 
J TTA CTT TGG GTT TAA 
3 GTA ATT TTG GTA TAA 
5 TTA ATC ACA GTA TAA 
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FIG. 3. Nucleotide sequences of mini-genes and amino acid 
sequences of the encoded peptides expressed in erythromycin-
resistant clones isolated on plates with 150 /xg/ml erythromycin 
(A), 1 mg/ml erythromycin (B), and randomly picked unselected 
clones (C) from the 5-codon library. Conserved Leu and lie in the 
third position and hydrophobic amino acids in the C-terminal position 
of the peptide sequence are underlined. Asterisks in the peptide se­
quences correspond to stop codons in peptide mini-genes. 
tion from sequences of peptides from unselected clones (Fig. 3, 
A and C) and exhibited a clear preference for certain amino 
acids in positions three and five. More than two-thirds of se­
lected peptides had either leucine or isoleucine in the third 
position, and most E-peptides had a hydrophobic amino acid, 
predominantly valine, at the C terminus. A similar trend was 
observed by S. Douthwaite, who isolated erythromycin resist­
ance peptides from a slightly different library.2 Altogether, 
Leu/Ile in the third position or a nonpolar amino acid in the 
fifth position could be found in 48 out of 52 E-peptide se­
quences. Only four of the E-peptides isolated from the library, 
MVQLR, MNWKR, MINQT, MYMLT, together with the rRNA-
encoded E-peptide, MRMLT, do not conform to the consensus, 
though three of these peptides, MVQLR, MYMLT and MRMLT, 
have Leu in the fourth position, which might possibly compen­
sate for the lack of Leu or lie in the third position. 
The relative efficiency of various E-peptides was assessed by 
comparing growth of the clones in liquid culture in the presence 
of a subinhibitory concentration of erythromycin (Fig. 4). A 
good correlation was observed between growth rate of clones in 
the presence of the drug and the presence of Leu or lie in the 
third position and a hydrophobic amino acid at the C terminus 
1S. Douthwaite, personal communication. 
4* 
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FIG. 4. Growth of clones expressing various E-peptides in the 
presence of a subinhibitory concentration of erythromycin. The 
relative growth is expressed as a ratio of optical density (at 650 nm) of 
cultures grown in the presence of 100 /ig/ml ampicillin, 2 mM IPTG, and 
100 fig/ml erythromycin to the optical density of cultures grown in the 
presence of only ampicillin and IPTG (see "Experimental Procedures" 
for details). The amino acid sequences of peptides expressed in the 
clones is shown at the bottom. Black bars correspond to peptides having 
Leu or lie in the third position and a hydrophobic amino acid at the C 
terminus. The peptide MRMLT was encoded in a 34-nucleotide frag­
ment of the 23 S rRNA and was expressed from the pPOTl vector (8). 
The bar at the very right shows the growth of cells transformed with an 
empty pPOTlAE vector. 
of the peptide. Peptides that have both of these features group 
at the top of the activity histogram on Fig. 4. Of the 10 clones 
that show the best growth in the presence of erythromycin, 8 
peptides conform to this rule. Conversely, peptides with lower 
activity tend to lack either Leu or He in the third position or a 
hydrophobic amino acid at the C terminus. Thus, the nature of 
these two positions in the E-peptide structure appear to be 
important for peptide activity. 
This conclusion was further corroborated when Ery1 clones 
were selected on ampicillin/IPTG plates containing very high 
concentrations of erythromycin (1 mg/ml). From 16 different 
mini-gene sequences found in such clones, 15 encoded pen­
tapeptides that had Leu or lie in the third position; 14 such 
mini-genes also encoded a hydrophobic amino acid (predomi­
nantly Val) in the fifth position (Fig. 3B). 
To rule out a possible strain specificity of E-peptide action, 
the effect of one of the E-peptides, MSLKV (Fig. 4), was com­
pared in three E. coli strains differing in their sensitivity to 
erythromycin. Erythromycin-supersensitive strain DB10 (13) 
(erythromycin MIC 1 /ig/ml), wild type strain MRE600 (14) 
(MIC 8 /xg/ml), and intrinsically erythromycin-tolerant JM109 
(10) (MIC 100 /ig/ml) were transformed with the plasmid cod­
ing for the MSLKV E-peptide. As a control, all strains were 
transformed with plasmid isolated from a randomly picked, 
unselected clone coding for peptide MDVEQ, Transformation 
with the control plasmid did not change erythromycin sensitiv­
ity of any of the strains, whereas expression of the E-peptide in 
any of the three strains increased erythromycin MIC 3-4-fold 
(data not shown). Thus, E-peptide can confer erythromycin 
resistance in different E. coli strains. 
Resistance to Different Antibiotics—To investigate whether 
E-peptide expression affects sensitivity to antibiotics other 
than erythromycin, cells transformed with the plasmid coding 
for the E-peptide MSLKV were grown in the presence of several 
antibiotics known to interact with the large ribosomal subunit 
(Fig. 5). Expression of the E-peptide increased cell resistance 
erythromycin oleandomycin spiramycin chloramphenicol clindamycin 
FIG. 5. Sensitivity of cells transformed with an empty vector 
(open bars), an unselected plasmid-encoding peptide MDVEQ 
(striped bars), and a plasmid isolated from Ery1" cells expressing 
E-peptide MSLKV (black bars) to different antibiotics. Sensitiv­
ity is expressed as a ratio of optical density (at 650 nm) of cultures 
grown in the presence of 100 /ig/ml erythromycin, 1 mg/ml oleando­
mycin, 200 /xg/ml spiramycin, 1 /ig/ml chloramphenicol, or 50 /ig/ml 
clindamycin to cultures grown in the absence of the drug. All cultures 
nevertheless contained 100 /ig/ml ampicillin and 2 MM IPTG. 
not only to erythromycin but also to two other macrolide anti­
biotics, spiramycin and oleandomycin, whereas sensitivity to 
chloramphenicol and clindamycin was not affected. 
DISCUSSION 
In the present study we asked the question, Which proper­
ties of a peptide make possible its functional interaction with 
the ribosome resulting in resistance to erythromycin? To an­
swer this question, we used random mini-gene libraries for 
isolation of a variety of erythromycin resistance peptides. The 
use of mini-gene expression libraries has a number of advan­
tages compared with the other combinatorial methods exploit­
ing libraries of synthetic peptides (15) or phage display librar­
ies (16). First, it is much easier to synthesize a random DNA 
sequence of the peptide gene than a random amino acid se­
quence of the peptide itself, leading to better representation of 
a random peptide sequence space in a mini-gene library. Sec­
ond, phenotypic selection permits not only screening of hun­
dreds of thousands of peptide sequences in a single experiment 
but also amplification of the "signal" (the selected sequences) 
by growing cells that passed the selection. Third, in contrast to 
phage display libraries where a random amino acid sequence is 
expressed as a segment of a larger protein, the mini-gene 
library peptides are expressed in their free form, which can be 
critical for assessing functionality of the peptide. Because of 
these advantages, random mini-gene libraries can be used for 
isolation of different functional peptides including enzyme co-
factors, inhibitors, etc. 
In our experiments, a number of clones expressing erythro­
mycin resistance peptides were isolated from 21- and 5-codon 
libraries. Comparison of peptide sequences allowed us to draw 
the first conclusions about the sequence and size requirements 
for peptide activity. Thus, screening of the 21-codon library 
primarily revealed the preferred size of erythromycin resist­
ance peptides. Each of the random codons in the library mini-
gene can be either 1 out of a possible 61 sense codons or 1 of the 
3 stop codons. The probability that, out of 20 random codons, 
none will be a terminator codon is (61/64)20 = 0.38; therefore, 
about two-thirds of the clones in the 21-codon library are ex­
pected to have in-frame stop codons. Indeed, as expected, a 
broad distribution of sizes of the encoded peptides were found 
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in unselected, randomly picked clones. In contrast, the majority 
of peptides expressed in Eryr clones fell within an amazingly 
narrow size range; 11 out of 12 peptides were 4, 5, or 6 amino 
acids long. Though it is possible that more extensive screening 
could reveal some functional peptides larger than hexapep-
tides, this experiment showed a clear tendency of erythromycin 
resistance peptides to be 4-6 amino acids long. In agreement 
with this finding, the originally described rRNA-encoded E-
peptide was 5 amino acids long (8). 
Previously it had been demonstrated that any mutation 
eliminating the stop codon of the rRNA-encoded E-peptide 
abolished erythromycin resistance (8). This showed that a mere 
presence of the E-peptide sequence at the N terminus of a 
longer polypeptide could not render ribosomes resistant to 
erythromycin. The results of screening a 21-codon library not 
only confirmed this observation but also indicated, that the 
E-peptide sequence is not functional when present at the C 
terminus of a longer oligopeptide (otherwise we could isolate 
clones coding for long peptides where a critical sequence would 
be located close to the C terminus). Thus, we can conclude that 
an erythromycin resistance peptide cannot be part of a longer 
protein and that the size of the peptide is essential for its 
activity. The strict size limitation may mean that the peptide 
binding site cannot accommodate a longer polypeptide. 
If analysis of clones isolated from the 21-codon library re­
vealed peptide size preference, then screening the 5-codon li­
brary provided clues to the sequence features that are impor­
tant for E-peptide activity. Comparison of pentapeptide 
sequences found in Eryr clones selected at 150 (ig/ml erythro­
mycin showed a strong tendency of E-peptides to have Leu or 
lie in the third position and a hydrophobic amino acid in the 
C-terminal position. Not only did these sequence signatures 
appear in the majority of isolated E-peptides (Fig. 3A), but 
there is also a correlation between the degree of peptide activ­
ity and the presence of Leu or lie in the third position and a 
hydrophobic amino acid at the C terminus (Fig. 4). Peptides 
expressed in clones growing at a very high concentration of 
erythromycin (1 mg/ml) show even stronger selectivity at posi­
tions 3 and 5; most of such peptides (with only one exception) 
have Leu or lie in the third position, and all peptides but one 
have a hydrophobic amino acid, most commonly Val, at the C 
terminus (Fig. 3B). In addition, peptides expressed in the 
highly resistant cells frequently have hydrophobic amino acids 
at the second and fourth positions: 14 out of 16 clones resistant 
to 1 mg/ml erythromycin express peptides with a hydrophobic 
amino acid in the second position, and in 8 of these peptides, a 
hydrophobic amino acid is present also at the fourth position. 
As a result, most of the peptides isolated from highly resistant 
clones are very hydrophobic, suggesting that the peptide bind­
ing site is also of a hydrophobic nature and presumably not 
exposed to the solvent. 
The ribosome appears to be the primary target of action of 
E-peptides since translation of the E-peptide mRNA in vitro 
rendered ribosomes resistant to erythromycin (8). At the same 
time, synthetic E-peptide did not affect sensitivity of the cell-
free translation system to erythromycin. This led to a hypoth­
esis that E-peptide enters the site of its action co-translation-
ally and acts in eis, affecting properties only of that ribosome on 
which it has been translated. The simplest way in which E-
peptide can render the ribosome resistant to erythromycin is by 
direct blocking of the drug binding site on the ribosome. This 
hypothesis is in a good agreement with the known mode of 
erythromycin action and the eis nature of the E-peptide effect. 
Erythromycin interacts with a vacant ribosome in the vicinity 
of the peptidyltransferase center and inhibits protein synthesis 
by sterically hindering growth of the nascent peptide (17). In 
] 30S SUBUNIT 
FIG. 6. Proposed model of E-peptide action. Erythromycin bind­
ing site (ERY) is shown in gray, and the binding sites of chloramphen­
icol (CAM) and clindamycin (CLD) are shown as open triangles. The 
third position of the peptide, commonly represented by Leu (as shown in 
the figure) or lie, is assumed to overlap with the erythromycin binding 
site. The conserved amino acids (N-terminal formyl methionine, the 
third Leu or He, and C-terminal hydrophobic amino acid commonly 
represented by Val, as shown in the figure) may form specific contacts 
with rRNA or ribosomal proteins. 
vitro, the antibiotic does not inhibit formation of the first pep­
tide bond, but it can inhibit the peptidyltransferase reaction 
when the donor substrate becomes 2 or more amino acids long 
(7, 18); nascent peptide chains longer than 2-5 amino acids 
(depending on the nature of polymerized amino acids) prevent 
erythromycin binding (19-21). Therefore, in the cell, erythro­
mycin can bind only to the vacant ribosome that has already 
released a newly synthesized protein but before several amino 
acids of a newly initiated protein are polymerized. If translated 
E-peptide does not leave the ribosome and remains tightly 
bound, the erythromycin binding site will be blocked, and the 
ribosome will be immune to erythromycin. A newly initiated 
nascent peptide may possibly go "around" the bound E-peptide 
or, alternatively, displace it. 
A model of E-peptide-ribosome interaction is shown in Fig. 6. 
The binding site of E-peptide is located most probably in the 
large ribosomal subunit, in or immediately near the nascent 
peptide channel, and overlaps with the erythromycin binding 
site (shown in shading in Fig. 6). Erythromycin starts to inhibit 
protein synthesis at a step when the third amino acid is added 
to the growing nascent peptide (22); therefore, if the C-terminal 
peptide residue is positioned in the ribosomal P-site, then the 
third residue from the C terminus would be located very close 
to the hypothetical erythromycin binding site. The bulky hy­
drophobic side chain of leucine or isoleucine may interfere with 
interaction of erythromycin with its binding site in the vicinity 
of the peptidyltransferase center. The peptide may enter its 
binding site co-translationally from the side of the peptidyl­
transferase center; this would explain a cis-mode of E-peptide 
action. E-peptide binding is probably stabilized by the interac­
tion of the essential amino acids with the ribosome compo­
nents, rRNA or proteins. Three amino acid positions in the 
peptide appear to be primarily important. Besides Leu or lie in 
the third position and a hydrophobic residue at the C terminus, 
the N-terminal formyl methionine may be also critical for pep­
tide binding. Though importance of fMet is difficult to assess 
since by default it is present in all library-coded E-peptides, the 
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fact that E-peptide cannot be part of a longer protein suggests 
that the position or formylation of the N-terminal methionine is 
crucial for peptide activity. 
Expression of E-peptide rendered cells resistant to other 
macrolide antibiotics: oleandomycin, which is similar to eryth­
romycin and has a 14-atom lactone ring, and spiramycin, a 
macrolide with a 16-atom ring. At the same time, E-peptide did 
not affect cell sensitivity to structurally different chloramphen­
icol and clindamycin. All drugs tested compete for binding to 
the ribosome (23); however, the binding sites of chloramphen­
icol and clindamycin do not precisely coincide with the binding 
site of macrolides, as demonstrated by RNA footprinting and 
the difference in the mode of action of these drugs (17, 24, 25). 
Thus, the site of E-peptide action probably overlaps specifically 
with the binding site of macrolides but not with that of other 
antibiotics interacting with the ribosome in the vicinity of the 
peptidyltransferase center. 
In the proposed model, E-peptide is assumed to interact with 
the large ribosomal subunit in the vicinity of the peptidyltrans­
ferase center (Fig. 6). A similar site of action was proposed for 
the cis-acting peptides regulating expression of erm, cat, and 
cmlA antibiotic-resistant genes (2, 26). These peptides, acting 
in a form of peptidyl tRNA, cause ribosome stalling on mRNA 
in the presence of low, noninhibitory concentrations of eryth­
romycin (27) or chloramphenicol (28). It is conceivable that 
erythromycin resistance E-peptides and regulatory cis-acting 
peptides may utilize a basically similar mechanism where tight 
binding of a peptide to the ribosome in the vicinity of the 
peptidyltransferase center causes erythromycin resistance in 
the case of E-peptide or ribosome stalling in the case of regu­
latory peptides of erm, cat, and cmlA genes. The lack of appar­
ent similarity between the consensus sequence of E-peptide 
and sequences of other cis-acting peptides may be related to the 
fact that stalling peptides become active only in the presence of 
low concentrations of chloramphenicol or erythromycin. Appli­
cation of a random library approach, which proved useful in the 
E-peptide studies, may provide insights into functionally im­
portant features of other eis-acting peptides and may eventu­
ally lead to a better understanding of how the ribosome "talks" 
to the protein it is synthesizing. 
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